201
|
Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon TJ, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Würschmidt F, Schem C, Bechtner C, Würstlein R, Fehm T, Möbus V, Burchardi N, Loibl S, Müller V. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer 2018; 102:1-9. [PMID: 30099223 DOI: 10.1016/j.ejca.2018.07.004] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Accepted: 07/03/2018] [Indexed: 11/17/2022]
Abstract
BACKGROUND Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited. METHODS We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions. RESULTS Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percentage of patients with luminal-like tumours increased (28%-34%; p = 0.0331). Patients with BMs in the posterior fossa were more often HER2 positive (n = 169/314, 53.8%) than those diagnosed with triple-negative (n = 65/314, 20.7%) or luminal-like primary breast cancer (n = 80/314, 25.5%), (p < 0.0001). Median overall survival (OS) time after development of BMs for the overall cohort was 7.4 months (95% confidence interval [CI]: 6.7-8.0 months). One-year survival rate was 37.7% (95% CI: 35.2-40.1). Patients with HER2-positive tumours had the longest median OS of 11.6 months (95% CI: 10.0-13.4) compared with 5.9 months (95% CI: 5.0-7.2) for patients with luminal-like and 4.6 months (95% CI: 3.9-5.4) for patients with triple-negative tumours. Patients with HER2-positive tumours who received anti-HER2 treatment had longer median OS than those without (17.1 months versus 7.2 months, p < 0.0001). CONCLUSIONS Prognosis of patients after developing BMs varies significantly according to the subtype. The outcome in this cohort is similarly poor in triple-negative and HR-positive/HER2-negative patients. Our results underline the high medical need for improvement of treatment and prevention strategies for BMs in breast cancer patients.
Collapse
Affiliation(s)
- I Witzel
- University Medical Center Hamburg-Eppendorf, Department of Gynecology, Hamburg, Germany.
| | - E Laakmann
- University Medical Center Hamburg-Eppendorf, Department of Gynecology, Hamburg, Germany.
| | - R Weide
- Oncological Outpatient Department, Koblenz, Germany.
| | - T Neunhöffer
- HELIOS Dr. Horst Schmidt Clinic Wiesbaden, Wiesbaden, Germany.
| | - T-J Park-Simon
- Hannover Medical School, Department of Gynecology, Hannover, Germany.
| | - M Schmidt
- Department of Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
| | - T Hesse
- Agaplesion Diakonie Clinic Rotenburg, Department of Gynecology, Rotenburg, Germany.
| | - A Polasik
- Department of Gynecology and Obstetrics, University Medical Center Ulm, Germany.
| | - S Mohrmann
- Duesseldorf University Hospital, Department of Gynecology, Duesseldorf, Germany.
| | - F Würschmidt
- Radiologische Allianz Hamburg, Hamburg, Germany.
| | - C Schem
- University Medical Center-UKSH, Department of Gynecology, Kiel, Germany; Mammazentrum, Krankenhaus Jerusalem, Hamburg, Germany.
| | - C Bechtner
- Frauenklinik, Memmingen Hospital, Germany.
| | - R Würstlein
- Department of Gynecology and Obstetrics, Ludwig-Maximilian-University Munich, Germany.
| | - T Fehm
- Translational Research Board of the Gynecological Oncology Working Group (AGO-Trafo), Germany.
| | - V Möbus
- Breast Study Group of the Gynecological Oncology Working Group (AGO-B), Germany.
| | - N Burchardi
- German Breast Group GmbH, Neu-Isenburg, Germany.
| | - S Loibl
- German Breast Group GmbH, Neu-Isenburg, Germany.
| | - V Müller
- University Medical Center Hamburg-Eppendorf, Department of Gynecology, Hamburg, Germany.
| |
Collapse
|
202
|
Klaas M, Schlottmann E, Flayac H, Laussy FP, Gericke F, Schmidt M, Helversen MV, Beyer J, Brodbeck S, Suchomel H, Höfling S, Reitzenstein S, Schneider C. Photon-Number-Resolved Measurement of an Exciton-Polariton Condensate. Phys Rev Lett 2018; 121:047401. [PMID: 30095927 DOI: 10.1103/physrevlett.121.047401] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Indexed: 06/08/2023]
Abstract
We measure the full photon-number distribution emitted from a Bose condensate of microcavity exciton polaritons confined in a micropillar cavity. The statistics are acquired by means of a photon-number-resolving transition edge sensor. We directly observe that the photon-number distribution evolves with the nonresonant optical excitation power from geometric to quasi-Poissonian statistics, which is canonical for a transition from a thermal to a coherent state. Moreover, the photon-number distribution allows one to evaluate the higher-order photon correlations, shedding further light on the coherence formation and phase transition of the polariton condensate. The experimental data are analyzed in terms of thermal-coherent states, which gives direct access to the thermal and coherent fraction from the measured distributions. These results pave the way for a full understanding of the contribution of interactions in light-matter condensates in the coherence buildup at threshold.
Collapse
Affiliation(s)
- M Klaas
- Technische Physik, Wilhelm-Conrad-Röntgen-Research Center for Complex Material Systems, Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany
| | - E Schlottmann
- Institut für Festkörperphysik, Technische Universität Berlin, Hardenbergstraße 36, D-10623, Berlin, Germany
| | - H Flayac
- Institute of Physics, Ecole Polytechnique Federale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - F P Laussy
- Faculty of Science and Engineering, University of Wolverhampton, Wulfruna St, Wolverhampton WV1 1LY, United Kingdom
- Russian Quantum Center, Novaya 100, 143025 Skolkovo, Moscow Region, Russia
| | - F Gericke
- Institut für Festkörperphysik, Technische Universität Berlin, Hardenbergstraße 36, D-10623, Berlin, Germany
| | - M Schmidt
- Institut für Festkörperphysik, Technische Universität Berlin, Hardenbergstraße 36, D-10623, Berlin, Germany
- Physikalisch-Technische Bundesanstalt, Abbestrasse 2-12, 10587 Berlin, Germany
| | - M V Helversen
- Institut für Festkörperphysik, Technische Universität Berlin, Hardenbergstraße 36, D-10623, Berlin, Germany
| | - J Beyer
- Physikalisch-Technische Bundesanstalt, Abbestrasse 2-12, 10587 Berlin, Germany
| | - S Brodbeck
- Technische Physik, Wilhelm-Conrad-Röntgen-Research Center for Complex Material Systems, Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany
| | - H Suchomel
- Technische Physik, Wilhelm-Conrad-Röntgen-Research Center for Complex Material Systems, Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany
| | - S Höfling
- Technische Physik, Wilhelm-Conrad-Röntgen-Research Center for Complex Material Systems, Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany
- SUPA, School of Physics and Astronomy, University of St Andrews, St Andrews KY16 9SS, United Kingdom
| | - S Reitzenstein
- Institut für Festkörperphysik, Technische Universität Berlin, Hardenbergstraße 36, D-10623, Berlin, Germany
| | - C Schneider
- Technische Physik, Wilhelm-Conrad-Röntgen-Research Center for Complex Material Systems, Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany
| |
Collapse
|
203
|
Schmidt M, Serror K, Chaouat M, Mimoun M, Boccara D. Prise en charge des cicatrices hypopigmentées post-brûlure. ANN CHIR PLAST ESTH 2018; 63:246-254. [DOI: 10.1016/j.anplas.2017.10.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Accepted: 10/11/2017] [Indexed: 10/18/2022]
|
204
|
Woolcot T, Kousi E, Wells E, Aitken K, Taylor H, Schmidt M. An Evaluation of Marker-based Registration of CT and MR Examinations for Liver SABR Planning. Clin Oncol (R Coll Radiol) 2018. [DOI: 10.1016/j.clon.2018.02.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
205
|
Visser L, Hoogstraat M, Elshof L, Leeuwen FV, Rutgers E, Schaapveld M, Schmidt M, Lips E, Wesseling J. PO-070 Identification of risk factors for subsequent invasive breast cancer after primary DCIS by transcriptomic profiling. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
206
|
Quaas A, Waldschmidt D, Alakus H, Zander T, Heydt C, Goeser T, Daheim M, Kasper P, Plum P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Göbel H, Tharun L, Buettner R, Merkelbach-Bruse S. Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel. BMC Gastroenterol 2018; 18:75. [PMID: 29855275 PMCID: PMC5984468 DOI: 10.1186/s12876-018-0803-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2017] [Accepted: 05/23/2018] [Indexed: 01/04/2023] Open
Abstract
Background Adenocarcinomas or combined adeno-neuroendocrine carcinomas (MANEC) of small bowel usually have a dismal prognosis with limited systemic therapy options. This is the first description of a patient showing a germline-related BRCA1 mutated MANEC of his ileum. The tumor presented a susceptibility to a combined chemotherapy and the PARP1-inhibitor olaparib. Case presentation A 74-year old male patient presented with a metastasized MANEC of his ileum. Due to clinical symptoms his ileum-tumor and the single brain metastasis were removed. We verified the same pathogenic (class 5) BRCA1 mutation in different tumor locations. There was no known personal history of a previous malignant tumor. Nevertheless we identified his BRCA1 mutation as germline-related. A systemic treatment was started including Gemcitabine followed by selective internal radiotherapy (SIRT) to treat liver metastases and in the further course Capecitabine but this treatment finally failed after 9 months and all liver metastases showed progression. The treatment failure was the reason to induce an individualized therapeutic approach using combined chemotherapy of carboplatin, paclitaxel and the Poly (ADP-ribose) polymerase- (PARP)-inhibitor olaparib analogous to the treatment protocol of Oza et al. All liver metastases demonstrated with significant tumor regression after 3 months and could be removed. In his most current follow up from December 2017 (25 months after his primary diagnosis) the patient is in a very good general condition without evidence for further metastases. Conclusion We present first evidence of a therapy susceptible germline-related BRCA1 mutation in small bowel adeno-neuroendocrine carcinoma (MANEC). Our findings offer a personalized treatment option. The germline background was unexpected in a 74-year old man with no previously known tumor burden. We should be aware of the familiar background in tumors of older patients as well.
Collapse
Affiliation(s)
- A Quaas
- Institute of Pathology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany. .,Gastrointestinal Cancer Group Cologne, Cologne, Germany.
| | - D Waldschmidt
- Department of Hepato- and Gastroenterology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - H Alakus
- Department of Visceral Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.,Gastrointestinal Cancer Group Cologne, Cologne, Germany
| | - T Zander
- Department of Oncology and Hematology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.,Gastrointestinal Cancer Group Cologne, Cologne, Germany
| | - C Heydt
- Institute of Pathology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - T Goeser
- Department of Hepato- and Gastroenterology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - M Daheim
- Department of Hepato- and Gastroenterology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - P Kasper
- Department of Hepato- and Gastroenterology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - P Plum
- Department of Visceral Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - C Bruns
- Department of Visceral Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - A Brunn
- Institute of Neuropathology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - W Roth
- Institute of Pathology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany
| | - N Hartmann
- Institute of Pathology, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany
| | - A Bunck
- Department of Radiology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - M Schmidt
- Department of Nuclear-Medicine, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - H Göbel
- Institute of Pathology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - L Tharun
- Institute of Pathology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - R Buettner
- Institute of Pathology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| | - S Merkelbach-Bruse
- Institute of Pathology, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany
| |
Collapse
|
207
|
Abdul-Razak HH, Rocca CJ, Howe SJ, Alonso-Ferrero ME, Wang J, Gabriel R, Bartholomae CC, Gan CHV, Garín MI, Roberts A, Blundell MP, Prakash V, Molina-Estevez FJ, Pantoglou J, Guenechea G, Holmes MC, Gregory PD, Kinnon C, von Kalle C, Schmidt M, Bueren JA, Thrasher AJ, Yáñez-Muñoz RJ. Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency. Sci Rep 2018; 8:8214. [PMID: 29844458 PMCID: PMC5974076 DOI: 10.1038/s41598-018-26439-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Accepted: 05/08/2018] [Indexed: 11/09/2022] Open
Abstract
Genome editing is the introduction of directed modifications in the genome, a process boosted to therapeutic levels by designer nucleases. Building on the experience of ex vivo gene therapy for severe combined immunodeficiencies, it is likely that genome editing of haematopoietic stem/progenitor cells (HSPC) for correction of inherited blood diseases will be an early clinical application. We show molecular evidence of gene correction in a mouse model of primary immunodeficiency. In vitro experiments in DNA-dependent protein kinase catalytic subunit severe combined immunodeficiency (Prkdc scid) fibroblasts using designed zinc finger nucleases (ZFN) and a repair template demonstrated molecular and functional correction of the defect. Following transplantation of ex vivo gene-edited Prkdc scid HSPC, some of the recipient animals carried the expected genomic signature of ZFN-driven gene correction. In some primary and secondary transplant recipients we detected double-positive CD4/CD8 T-cells in thymus and single-positive T-cells in blood, but no other evidence of immune reconstitution. However, the leakiness of this model is a confounding factor for the interpretation of the possible T-cell reconstitution. Our results provide support for the feasibility of rescuing inherited blood disease by ex vivo genome editing followed by transplantation, and highlight some of the challenges.
Collapse
Affiliation(s)
- H H Abdul-Razak
- AGCTlab.org, Centre for Gene and Cell Therapy, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway, University of London, Egham, UK
| | - C J Rocca
- AGCTlab.org, Centre for Gene and Cell Therapy, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway, University of London, Egham, UK
| | - S J Howe
- Infection, Immunity, Inflammation and Physiological Medicine Programme, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.,Gene Transfer Technology Group, UCL Institute for Women's Health, University College London, London, UK
| | - M E Alonso-Ferrero
- Infection, Immunity, Inflammation and Physiological Medicine Programme, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK
| | - J Wang
- Sangamo Therapeutics, Inc., Richmond, California, USA
| | - R Gabriel
- Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany
| | - C C Bartholomae
- Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany
| | - C H V Gan
- Infection, Immunity, Inflammation and Physiological Medicine Programme, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK
| | - M I Garín
- Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII)/Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
| | - A Roberts
- Department of Medical and Molecular Genetics, King's College London, London, UK
| | - M P Blundell
- Infection, Immunity, Inflammation and Physiological Medicine Programme, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK
| | - V Prakash
- AGCTlab.org, Centre for Gene and Cell Therapy, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway, University of London, Egham, UK
| | - F J Molina-Estevez
- AGCTlab.org, Centre for Gene and Cell Therapy, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway, University of London, Egham, UK.,Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII)/Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
| | - J Pantoglou
- AGCTlab.org, Centre for Gene and Cell Therapy, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway, University of London, Egham, UK
| | - G Guenechea
- Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII)/Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
| | - M C Holmes
- Sangamo Therapeutics, Inc., Richmond, California, USA
| | - P D Gregory
- Sangamo Therapeutics, Inc., Richmond, California, USA
| | - C Kinnon
- Infection, Immunity, Inflammation and Physiological Medicine Programme, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK
| | - C von Kalle
- Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany
| | - M Schmidt
- Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany
| | - J A Bueren
- Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII)/Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
| | - A J Thrasher
- Infection, Immunity, Inflammation and Physiological Medicine Programme, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.,Great Ormond Street Hospital NHS Foundation Trust, London, UK
| | - R J Yáñez-Muñoz
- AGCTlab.org, Centre for Gene and Cell Therapy, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway, University of London, Egham, UK.
| |
Collapse
|
208
|
Schneider S, Wolf D, Stolt MJ, Jin S, Pohl D, Rellinghaus B, Schmidt M, Büchner B, Goennenwein STB, Nielsch K, Lubk A. Induction Mapping of the 3D-Modulated Spin Texture of Skyrmions in Thin Helimagnets. Phys Rev Lett 2018; 120:217201. [PMID: 29883134 DOI: 10.1103/physrevlett.120.217201] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Revised: 03/29/2018] [Indexed: 06/08/2023]
Abstract
Envisaged applications of Skyrmions in magnetic memory and logic devices crucially depend on the stability and mobility of these topologically nontrivial magnetic textures in thin films. We present for the first time quantitative maps of the magnetic induction that provide evidence for a 3D modulation of the Skyrmionic spin texture. The projected in-plane magnetic induction maps as determined from in-line and off-axis electron holography carry the clear signature of Bloch Skyrmions. However, the magnitude of this induction is much smaller than the values expected for homogeneous Bloch Skyrmions that extend throughout the thickness of the film. This finding can only be understood if the underlying spin textures are modulated along the out-of-plane z direction. The projection of (the in-plane magnetic induction of) helices is further found to exhibit thickness-dependent lateral shifts, which show that this z modulation is accompanied by an (in-plane) modulation along the x and y directions.
Collapse
Affiliation(s)
- S Schneider
- Institute for Metallic Materials, IFW Dresden, Helmholtzstr. 20, 01069 Dresden, Germany
- Institut für Festkörper- und Materialphysik, Technische Universität Dresden, 01062 Dresden, Germany
| | - D Wolf
- Institute for Solid State Research, IFW Dresden, Helmholtzstr. 20, 01069 Dresden, Germany
| | - M J Stolt
- Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, Wisconsin 53706, USA
| | - S Jin
- Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, Wisconsin 53706, USA
| | - D Pohl
- Institute for Metallic Materials, IFW Dresden, Helmholtzstr. 20, 01069 Dresden, Germany
- Dresden Center for Nanoanalysis, Technische Universität Dresden, 01062 Dresden, Germany
| | - B Rellinghaus
- Institute for Metallic Materials, IFW Dresden, Helmholtzstr. 20, 01069 Dresden, Germany
- Dresden Center for Nanoanalysis, Technische Universität Dresden, 01062 Dresden, Germany
| | - M Schmidt
- Department Chemical Metal Science, Max Planck Institute for Chemical Physics of Solids, Nöthnitzer Str. 40, 01187 Dresden, Germany
| | - B Büchner
- Institute for Solid State Research, IFW Dresden, Helmholtzstr. 20, 01069 Dresden, Germany
| | - S T B Goennenwein
- Institut für Festkörper- und Materialphysik, Technische Universität Dresden, 01062 Dresden, Germany
- Center for Transport and Devices of Emergent Materials, Technische Universität Dresden, 01062 Dresden, Germany
| | - K Nielsch
- Institute for Metallic Materials, IFW Dresden, Helmholtzstr. 20, 01069 Dresden, Germany
- Institute of Materials Science, Technische Universität Dresden, Helmholtzstr. 7, 01069 Dresden, Germany
| | - A Lubk
- Institute for Solid State Research, IFW Dresden, Helmholtzstr. 20, 01069 Dresden, Germany
| |
Collapse
|
209
|
van Albada SJ, Rowley AG, Senk J, Hopkins M, Schmidt M, Stokes AB, Lester DR, Diesmann M, Furber SB. Performance Comparison of the Digital Neuromorphic Hardware SpiNNaker and the Neural Network Simulation Software NEST for a Full-Scale Cortical Microcircuit Model. Front Neurosci 2018; 12:291. [PMID: 29875620 PMCID: PMC5974216 DOI: 10.3389/fnins.2018.00291] [Citation(s) in RCA: 78] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 04/13/2018] [Indexed: 01/12/2023] Open
Abstract
The digital neuromorphic hardware SpiNNaker has been developed with the aim of enabling large-scale neural network simulations in real time and with low power consumption. Real-time performance is achieved with 1 ms integration time steps, and thus applies to neural networks for which faster time scales of the dynamics can be neglected. By slowing down the simulation, shorter integration time steps and hence faster time scales, which are often biologically relevant, can be incorporated. We here describe the first full-scale simulations of a cortical microcircuit with biological time scales on SpiNNaker. Since about half the synapses onto the neurons arise within the microcircuit, larger cortical circuits have only moderately more synapses per neuron. Therefore, the full-scale microcircuit paves the way for simulating cortical circuits of arbitrary size. With approximately 80, 000 neurons and 0.3 billion synapses, this model is the largest simulated on SpiNNaker to date. The scale-up is enabled by recent developments in the SpiNNaker software stack that allow simulations to be spread across multiple boards. Comparison with simulations using the NEST software on a high-performance cluster shows that both simulators can reach a similar accuracy, despite the fixed-point arithmetic of SpiNNaker, demonstrating the usability of SpiNNaker for computational neuroscience applications with biological time scales and large network size. The runtime and power consumption are also assessed for both simulators on the example of the cortical microcircuit model. To obtain an accuracy similar to that of NEST with 0.1 ms time steps, SpiNNaker requires a slowdown factor of around 20 compared to real time. The runtime for NEST saturates around 3 times real time using hybrid parallelization with MPI and multi-threading. However, achieving this runtime comes at the cost of increased power and energy consumption. The lowest total energy consumption for NEST is reached at around 144 parallel threads and 4.6 times slowdown. At this setting, NEST and SpiNNaker have a comparable energy consumption per synaptic event. Our results widen the application domain of SpiNNaker and help guide its development, showing that further optimizations such as synapse-centric network representation are necessary to enable real-time simulation of large biological neural networks.
Collapse
Affiliation(s)
- Sacha J van Albada
- Institute of Neuroscience and Medicine (INM-6), Institute for Advanced Simulation (IAS-6), JARA Institute Brain Structure-Function Relationships (INM-10), Jülich Research Centre Jülich, Germany
| | - Andrew G Rowley
- Advanced Processor Technologies Group, School of Computer Science, University of Manchester, Manchester, United Kingdom
| | - Johanna Senk
- Institute of Neuroscience and Medicine (INM-6), Institute for Advanced Simulation (IAS-6), JARA Institute Brain Structure-Function Relationships (INM-10), Jülich Research Centre Jülich, Germany
| | - Michael Hopkins
- Advanced Processor Technologies Group, School of Computer Science, University of Manchester, Manchester, United Kingdom
| | - Maximilian Schmidt
- Institute of Neuroscience and Medicine (INM-6), Institute for Advanced Simulation (IAS-6), JARA Institute Brain Structure-Function Relationships (INM-10), Jülich Research Centre Jülich, Germany.,Laboratory for Neural Circuit Theory, RIKEN Brain Science Institute, Wako, Japan
| | - Alan B Stokes
- Advanced Processor Technologies Group, School of Computer Science, University of Manchester, Manchester, United Kingdom
| | - David R Lester
- Advanced Processor Technologies Group, School of Computer Science, University of Manchester, Manchester, United Kingdom
| | - Markus Diesmann
- Institute of Neuroscience and Medicine (INM-6), Institute for Advanced Simulation (IAS-6), JARA Institute Brain Structure-Function Relationships (INM-10), Jülich Research Centre Jülich, Germany.,Department of Physics, Faculty 1, RWTH Aachen University, Aachen, Germany.,Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Steve B Furber
- Advanced Processor Technologies Group, School of Computer Science, University of Manchester, Manchester, United Kingdom
| |
Collapse
|
210
|
Bargiotas P, Dietmann A, Haynes AG, Calle MG, Kallweit U, Schmidt M, Mathis J, Bassetti CL. 0631 Diagnostic Accuracy And Validity Of The Swiss Narcolepsy Scale For The Diagnosis Of Type 1 And Type 2 Narcolepsy Against Other Central Disorders Of Hypersomnolence. Sleep 2018. [DOI: 10.1093/sleep/zsy061.630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- P Bargiotas
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - A Dietmann
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - A G Haynes
- Clinical Trials Unit, University of Bern, Bern, SWITZERL
| | - M G Calle
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - U Kallweit
- Dept. of Neurology, Narcolepsy Center, Helios Klinik Hagen-Ambrock, Hagen, GERMANY
| | - M Schmidt
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - J Mathis
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - C L Bassetti
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| |
Collapse
|
211
|
Calle MG, Dietmann A, Bargiotas P, Kallweit U, Schmidt M, Ott S, Gugger M, Mathis J, Bassetti CL. 0733 The Bern Sleep-wake Registry: Demographics And Clinical Characteristics Of The First 6,831 Patients. Sleep 2018. [DOI: 10.1093/sleep/zsy061.732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M G Calle
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - A Dietmann
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - P Bargiotas
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - U Kallweit
- Dept. of Neurology, Narcolepsy Center, Helios Kliniken, Hagen, GERMANY
| | - M Schmidt
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - S Ott
- Dept. of Pulmonology, University Hospital and University of Bern, Bern, SWITZERLAND
| | - M Gugger
- Dept. of Pulmonology, University Hospital and University of Bern, Bern, SWITZERLAND
| | - J Mathis
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| | - C L Bassetti
- Sleep Wake Epilepsy Center and Dept. of Neurology, University Hospital and University of Bern, Bern, SWITZERL
| |
Collapse
|
212
|
Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, Schmidt-Wolf I, Wildenhain C, Zimmer B, Essler M. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein]. Urologe A 2018; 57:709-713. [PMID: 29671080 DOI: 10.1007/s00120-018-0642-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In the last 3 years, Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA-RLT) has received increasing attention in nuclear medicine as a new form of treatment for castration-resistant metastatic prostate cancer. This therapy combines the radionuclide Lutetium-177, which has been therapeutically used in nuclear medicine for many years, with a molecular target of the transmembrane prostate-specific membrane antigen expressed by prostate cancer cells. Since there are no prospective randomized studies on Lu-177-PSMA-RLT and the question of reimbursement has repeatedly been the subject of review by the MDK Nordrhein (Medischenische Dienst der Krankenversicherung), there was a desire because of the increasing number of patients being treated to clarify under which circumstances Lu-177-PSMA-RLT can be reimbursed by German statutory health insurance. The goals of this article are to help treating physicians understand how this new therapy option works, to integrate it in the overall therapy concept for castration-resistant metastatic prostate cancer, and, above all, to use Lu-177-PSMA-RLT-based on the current data-at the right place in the therapy sequence of castration-resistant metastatic prostate cancer.
Collapse
Affiliation(s)
- H Ahmadzadehfar
- Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland.
| | - P Albers
- Klinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - A Bockisch
- Klinik für Nuklearmedizin, Universitätsklinikum Essen, Essen, Deutschland
| | - M Boegemann
- Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Münster, Deutschland
| | - C Böhme
- Abteilung für Medizin-Controlling, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - W Burchert
- Herz- und Diabeteszentrum Bad Oeynhausen, Klinik für Nuklearmedizin, Bad Oeynhausen, Deutschland
| | - M Dietlein
- Klinik für Nuklearmedizin, Universitätsklinikum Köln, Köln, Deutschland
| | - A Drzezga
- Klinik für Nuklearmedizin, Universitätsklinikum Köln, Köln, Deutschland
| | - U Fabry
- Abteilung für Medizin-Controlling, Universitätsklinikum Aachen, Aachen, Deutschland
| | - G Feldmann
- Medizinische Klinik und Poliklinik III, Universitätsklinikum Bonn, Bonn, Deutschland
| | - A Heidenreich
- Klinik für Urologie, Universitätsklinikum Köln, Köln, Deutschland
| | - A Heinzel
- Klinik für Nuklearmedizin, Uniklinikum Aachen, Aachen, Deutschland
| | - K Herrmann
- Klinik für Nuklearmedizin, Universitätsklinikum Essen, Essen, Deutschland
| | - A Heyll
- KC Onkologie des GKV-SV und der MDK-Gemeinschaft, Düsseldorf, Deutschland
| | - C Höhling
- AOK Rheinland/Hamburg, Düsseldorf, Deutschland
| | - C Kreuzer
- MFB Stationäre Versorgung, MDK Nordrhein, Düsseldorf, Deutschland
| | - D Laufer
- Abteilung für Medizin-Controlling, Universitätsklinikum Bonn, Bonn, Deutschland
| | - R Mengel
- MFB Stationäre Versorgung, MDK Nordrhein, Düsseldorf, Deutschland
| | - F M Mottaghy
- Klinik für Nuklearmedizin, Uniklinikum Aachen, Aachen, Deutschland
| | - H-W Müller
- Klinik für Nuklearmedizin, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - S C Müller
- Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn, Bonn, Deutschland
| | - E Ost
- KC Onkologie des GKV-SV und der MDK-Gemeinschaft, Düsseldorf, Deutschland
| | - K Rahbar
- Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland
| | - W Reifenhäuser
- Abteilung für Medizin-Controlling, Universitätsklinikum Köln, Köln, Deutschland
| | - M Schäfers
- Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland
| | - C Schlenkhoff
- Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland
| | - M Schmidt
- Klinik für Nuklearmedizin, Universitätsklinikum Köln, Köln, Deutschland
| | - I Schmidt-Wolf
- Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn, Bonn, Deutschland
| | - C Wildenhain
- Abteilung für Medizin-Controlling, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - B Zimmer
- KC Onkologie des GKV-SV und der MDK-Gemeinschaft, Düsseldorf, Deutschland
| | - M Essler
- Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland
| |
Collapse
|
213
|
Schröder C, Engehart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Kirschner S, Buchali A. EP-1358: Correlation between changes in lung function and lung density after radiotherapy for thoracic cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31667-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
214
|
Scholtz K, Spies CD, Mörgeli R, Eckardt R, von Dossow V, Braun S, Sehouli J, Bahra M, Stief CG, Wernecke KD, Schmidt M. Risk factors for 30-day complications after cancer surgery in geriatric patients: a secondary analysis. Acta Anaesthesiol Scand 2018; 62:451-463. [PMID: 29359461 DOI: 10.1111/aas.13067] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Revised: 12/20/2017] [Accepted: 12/21/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND The aim was to analyse the association between severity of complications up to 30 days after surgery and pre-operative nutritional and physical performance parameters. METHODS The participants were a subsample of the previously published PERATECS study (ClinicalTrials.gov: NCT01278537) and included 517 onco-geriatric patients aged ≥ 65 years, undergoing thoracoabdominal, gynaecological, or urological surgery. Post-operative complications were classified according to the Clavien Classification System (CCS). Independent risk factors related to the severity of complications, defined as major complications (CCS IIIa-V) and graded complications (CCS grade 0-V), were analysed using logistic and ordinal regression, respectively. RESULTS In total, 132 patients suffered major post-operative complications. The development of major post-operative complications was independently associated with body mass index (BMI) < 20 kg/m2 , hypoalbuminaemia (< 30 g/l), longer duration of surgery, and specific tumour sites (upper gastrointestinal, gynaecological, colorectal) (all P < 0.05). Higher-grade complications were predicted by Timed Up and Go (TUG) > 20 s, hypoalbuminaemia (< 30 g/l), higher American Society of Anesthesiologists (ASA) status III-IV, longer duration of surgery (> 165 min), and specific tumour sites (upper gastrointestinal, gynaecological) (all P < 0.05). Mini Nutritional Assessment (MNA) scores and weight loss were not independent risk factors for the severity of complications. CONCLUSIONS Nutritional and physical performance risk factors that predicted the severity of complications differed between major and higher-grade post-operative complications, but hypoalbuminaemia independently predicted both. The results support the need for pre-operative risk screening. Due to the explorative nature of the study, further research is required in larger cohorts to corroborate these findings.
Collapse
Affiliation(s)
- K. Scholtz
- Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK); Charité - Universitätsmedizin Berlin; Berlin Germany
| | - C. D. Spies
- Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK); Charité - Universitätsmedizin Berlin; Berlin Germany
| | - R. Mörgeli
- Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK); Charité - Universitätsmedizin Berlin; Berlin Germany
| | - R. Eckardt
- Clinic for Geriatrics; St. Joseph Krankenhaus Berlin Tempelhof; GmbH Berlin Germany
| | - V. von Dossow
- Department of Anesthesiology; University Hospital Munich-Grosshadern; Ludwig-Maximilians-University; Munich Germany
| | - S. Braun
- Department of Anesthesiology; University Hospital Munich-Grosshadern; Ludwig-Maximilians-University; Munich Germany
| | - J. Sehouli
- Department of Gynaecology; Campus Virchow-Klinikum; Charité - Universitätsmedizin; Berlin Germany
| | - M. Bahra
- Department of Surgery; (CCM, CVK); Charité - Universitätsmedizin Berlin; Berlin Germany
| | - C. G. Stief
- Department of Urology; University Hospital Munich-Grosshadern; Ludwig-Maximilians-University; Munich Germany
| | - K.-D. Wernecke
- Charité - Universitätsmedizin Berlin and SOSTANA GmbH; Berlin Germany
| | - M. Schmidt
- Department of Anesthesiology and Intensive Care Medicine; Klinikum Barnim GmbH; Werner Forßmann Krankenhaus Eberswalde; Eberswalde Germany
| | | |
Collapse
|
215
|
Fog L, Sengeløv H, Schmidt M, Petersen P, Specht L. EP-1240: Oral mucositis, pain, IV opioid use and inpatient days after TBI delivered in 3 vs 6 fractions. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31550-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
216
|
Pathmanathan A, Schmidt M, Brand D, Delacroix L, Eccles C, Gordon A, Herbert T, McNair H, Van As N, Huddart R, Tree A. EP-1613: Comparison of prostate delineation on multi-modality imaging for MR-guided radiotherapy. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31922-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
217
|
Keisari Y, Cohen A, Efrati M, Schmidt M, Galalae R, Kelson I. PO-1033: Activation of specific anti-tumor immunity by alpha radiation based brachytherapy and immunotherapy. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31343-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
218
|
Acharya S, Adamová D, Adolfsson J, Aggarwal MM, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad N, Ahn SU, Aiola S, Akindinov A, Alam SN, Alba JLB, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfaro Molina R, Alici A, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Alves Garcia Prado C, Andrei C, Andreou D, Andrews HA, Andronic A, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Anwar R, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arnold OW, Arsene IC, Arslandok M, Audurier B, Augustinus A, Averbeck R, Azmi MD, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Baldisseri A, Ball M, Baral RC, Barbano AM, Barbera R, Barile F, Barioglio L, Barnaföldi GG, Barnby LS, Barret V, Bartalini P, Barth K, Bartsch E, Basile M, Bastid N, Basu S, Batigne G, Batyunya B, Batzing PC, Bearden IG, Beck H, Bedda C, Behera NK, Belikov I, Bellini F, Bello Martinez H, Bellwied R, Beltran LGE, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berenyi D, Bertens RA, Berzano D, Betev L, Bhasin A, Bhat IR, Bhati AK, Bhattacharjee B, Bhom J, Bianchi L, Bianchi N, Bianchin C, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas R, Biswas S, Blair JT, Blau D, Blume C, Boca G, Bock F, Bogdanov A, Boldizsár L, Bombara M, Bonomi G, Bonora M, Book J, Borel H, Borissov A, Borri M, Botta E, Bourjau C, Bratrud L, Braun-Munzinger P, Bregant M, Broker TA, Broz M, Brucken EJ, Bruna E, Bruno GE, Budnikov D, Buesching H, Bufalino S, Buhler P, Buncic P, Busch O, Buthelezi Z, Butt JB, Buxton JT, Cabala J, Caffarri D, Caines H, Caliva A, Calvo Villar E, Camerini P, Capon AA, Carena F, Carena W, Carnesecchi F, Castillo Castellanos J, Castro AJ, Casula EAR, Ceballos Sanchez C, Cerello P, Chandra S, Chang B, Chapeland S, Chartier M, Charvet JL, Chattopadhyay S, Chattopadhyay S, Chauvin A, Cherney M, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Choi K, Chojnacki M, Choudhury S, Chowdhury T, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Chung SU, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Colamaria F, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Connors ME, Contreras JG, Cormier TM, Corrales Morales Y, Cortés Maldonado I, Cortese P, Cosentino MR, Costa F, Costanza S, Crkovská J, Crochet P, Cuautle E, Cunqueiro L, Dahms T, Dainese A, Danisch MC, Danu A, Das D, Das I, Das S, Dash A, Dash S, De S, De Caro A, de Cataldo G, de Conti C, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, De Souza RD, Degenhardt HF, Deisting A, Deloff A, Deplano C, Dhankher P, Di Bari D, Di Mauro A, Di Nezza P, Di Ruzza B, Diaz Corchero MA, Dietel T, Dillenseger P, Divià R, Djuvsland Ø, Dobrin A, Domenicis Gimenez D, Dönigus B, Dordic O, Doremalen LVV, Dubey AK, Dubla A, Ducroux L, Duggal AK, Dupieux P, Ehlers RJ, Elia D, Endress E, Engel H, Epple E, Erazmus B, Erhardt F, Espagnon B, Esumi S, Eulisse G, Eum J, Evans D, Evdokimov S, Fabbietti L, Faivre J, Fantoni A, Fasel M, Feldkamp L, Feliciello A, Feofilov G, Ferencei J, Fernández Téllez A, Ferreiro EG, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Figueredo MAS, Filchagin S, Finogeev D, Fionda FM, Fiore EM, Floris M, Foertsch S, Foka P, Fokin S, Fragiacomo E, Francescon A, Francisco A, Frankenfeld U, Fronze GG, Fuchs U, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gajdosova K, Gallio M, Galvan CD, Ganoti P, Gao C, Garabatos C, Garcia-Solis E, Garg K, Gargiulo C, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Gianotti P, Giubellino P, Giubilato P, Gladysz-Dziadus E, Glässel P, Goméz Coral DM, Gomez Ramirez A, Gonzalez AS, Gonzalez V, González-Zamora P, Gorbunov S, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Grion N, Gronefeld JM, Grosa F, Grosse-Oetringhaus JF, Grosso R, Gruber L, Guber F, Guernane R, Guerzoni B, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Hadjidakis C, Hamagaki H, Hamar G, Hamon JC, Haque MR, Harris JW, Harton A, Hassan H, Hatzifotiadou D, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herghelegiu A, Herrera Corral G, Herrmann F, Hess BA, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hladky J, Hohlweger B, Horak D, Hornung S, Hosokawa R, Hristov P, Hughes C, Humanic TJ, Hussain N, Hussain T, Hutter D, Hwang DS, Iga Buitron SA, Ilkaev R, Inaba M, Ippolitov M, Irfan M, Isakov V, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadhav MB, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Jayarathna PHSY, Jena C, Jena S, Jercic M, Jimenez Bustamante RT, Jones PG, Jusko A, Kalinak P, Kalweit A, Kang JH, Kaplin V, Kar S, Karasu Uysal A, Karavichev O, Karavicheva T, Karayan L, Karczmarczyk P, Karpechev E, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khabanova Z, Khan P, Khan SA, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kielbowicz MM, Kileng B, Kim B, Kim D, Kim DJ, Kim H, Kim JS, Kim J, Kim M, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kiss G, Klay JL, Klein C, Klein J, Klein-Bösing C, Klewin S, Kluge A, Knichel ML, Knospe AG, Kobdaj C, Kofarago M, Kollegger T, Kolojvari A, Kondratiev V, Kondratyeva N, Kondratyuk E, Konevskikh A, Konyushikhin M, Kopcik M, Kour M, Kouzinopoulos C, Kovalenko O, Kovalenko V, Kowalski M, Koyithatta Meethaleveedu G, Králik I, Kravčáková A, Krivda M, Krizek F, Kryshen E, Krzewicki M, Kubera AM, Kučera V, Kuhn C, Kuijer PG, Kumar A, Kumar J, Kumar L, Kumar S, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kweon MJ, Kwon Y, La Pointe SL, La Rocca P, Lagana Fernandes C, Lai YS, Lakomov I, Langoy R, Lapidus K, Lara C, Lardeux A, Lattuca A, Laudi E, Lavicka R, Lazaridis L, Lea R, Leardini L, Lee S, Lehas F, Lehner S, Lehrbach J, Lemmon RC, Lenti V, Leogrande E, León Monzón I, Lévai P, Li S, Li X, Lien J, Lietava R, Lim B, Lindal S, Lindenstruth V, Lindsay SW, Lippmann C, Lisa MA, Litichevskyi V, Ljunggren HM, Llope WJ, Lodato DF, Loenne PI, Loginov V, Loizides C, Loncar P, Lopez X, López Torres E, Lowe A, Luettig P, Luhder JR, Lunardon M, Luparello G, Lupi M, Lutz TH, Maevskaya A, Mager M, Mahajan S, Mahmood SM, Maire A, Majka RD, Malaev M, Malinina L, Mal'Kevich D, Malzacher P, Mamonov A, Manko V, Manso F, Manzari V, Mao Y, Marchisone M, Mareš J, Margagliotti GV, Margotti A, Margutti J, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JAL, Martínez MI, Martínez García G, Martinez Pedreira M, Mas A, Masciocchi S, Masera M, Masoni A, Masson E, Mastroserio A, Mathis AM, Matyja A, Mayer C, Mazer J, Mazzilli M, Mazzoni MA, Meddi F, Melikyan Y, Menchaca-Rocha A, Meninno E, Mercado Pérez J, Meres M, Mhlanga S, Miake Y, Mieskolainen MM, Mihaylov D, Mihaylov DL, Mikhaylov K, Milano L, Milosevic J, Mischke A, Mishra AN, Miśkowiec D, Mitra J, Mitu CM, Mohammadi N, Mohanty B, Mohisin Khan M, Montes E, Moreira De Godoy DA, Moreno LAP, Moretto S, Morreale A, Morsch A, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mukherjee M, Mulligan JD, Munhoz MG, Münning K, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Narayan A, Naru MU, Natal da Luz H, Nattrass C, Navarro SR, Nayak K, Nayak R, Nayak TK, Nazarenko S, Nedosekin A, Negrao De Oliveira RA, Nellen L, Nesbo SV, Ng F, Nicassio M, Niculescu M, Niedziela J, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Nobuhiro A, Noferini F, Nomokonov P, Nooren G, Noris JCC, Norman J, Nyanin A, Nystrand J, Oeschler H, Oh S, Ohlson A, Okubo T, Olah L, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onderwaater J, Oppedisano C, Orava R, Oravec M, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Pacik V, Pagano D, Pagano P, Paić G, Palni P, Pan J, Pandey AK, Panebianco S, Papikyan V, Pappalardo GS, Pareek P, Park J, Parmar S, Passfeld A, Pathak SP, Paticchio V, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez Lezama E, Peskov V, Pestov Y, Petráček V, Petrov V, Petrovici M, Petta C, Pezzi RP, Piano S, Pikna M, Pillot P, Pimentel LODL, Pinazza O, Pinsky L, Piyarathna DB, Płoskoń M, Planinic M, Pliquett F, Pluta J, Pochybova S, Podesta-Lerma PLM, Poghosyan MG, Polichtchouk B, Poljak N, Poonsawat W, Pop A, Poppenborg H, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Puddu G, Pujahari P, Punin V, Putschke J, Rachevski A, Raha S, Rajput S, Rak J, Rakotozafindrabe A, Ramello L, Rami F, Rana DB, Raniwala R, Raniwala S, Räsänen SS, Rascanu BT, Rathee D, Ratza V, Ravasenga I, Read KF, Redlich K, Rehman A, Reichelt P, Reidt F, Ren X, Renfordt R, Reolon AR, Reshetin A, Reygers K, Riabov V, Ricci RA, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogochaya E, Rohr D, Röhrich D, Rokita PS, Ronchetti F, Rosas ED, Rosnet P, Rossi A, Rotondi A, Roukoutakis F, Roy A, Roy C, Roy P, Rubio Montero AJ, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Saarinen S, Sadhu S, Sadovsky S, Šafařík K, Saha SK, Sahlmuller B, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu PK, Saini J, Sakai S, Saleh MA, Salzwedel J, Sambyal S, Samsonov V, Sandoval A, Sarkar D, Sarkar N, Sarma P, Sas MHP, Scapparone E, Scarlassara F, Scharenberg RP, Scheid HS, Schiaua C, Schicker R, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schuchmann S, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Scott R, Šefčík M, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senosi K, Senyukov S, Serradilla E, Sett P, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma A, Sharma M, Sharma M, Sharma N, Sheikh AI, Shigaki K, Shou Q, Shtejer K, Sibiriak Y, Siddhanta S, Sielewicz KM, Siemiarczuk T, Silvermyr D, Silvestre C, Simatovic G, Simonetti G, Singaraju R, Singh R, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Slupecki M, Smirnov N, Snellings RJM, Snellman TW, Song J, Song M, Soramel F, Sorensen S, Sozzi F, Spiriti E, Sputowska I, Srivastava BK, Stachel J, Stan I, Stankus P, Stenlund E, Stocco D, Storetvedt MM, Strmen P, Suaide AAP, Sugitate T, Suire C, Suleymanov M, Suljic M, Sultanov R, Šumbera M, Sumowidagdo S, Suzuki K, Swain S, Szabo A, Szarka I, Tabassam U, Takahashi J, Tambave GJ, Tanaka N, Tarhini M, Tariq M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terasaki K, Terrevoli C, Teyssier B, Thakur D, Thakur S, Thomas D, Thoresen F, Tieulent R, Tikhonov A, Timmins AR, Toia A, Tripathy S, Trogolo S, Trombetta G, Tropp L, Trubnikov V, Trzaska WH, Trzeciak BA, Tsuji T, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Usai GL, Utrobicic A, Vala M, Van Der Maarel J, Van Hoorne JW, van Leeuwen M, Vanat T, Vande Vyvre P, Varga D, Vargas A, Vargyas M, Varma R, Vasileiou M, Vasiliev A, Vauthier A, Vázquez Doce O, Vechernin V, Veen AM, Velure A, Vercellin E, Vergara Limón S, Vernet R, Vértesi R, Vickovic L, Vigolo S, Viinikainen J, Vilakazi Z, Villalobos Baillie O, Villatoro Tello A, Vinogradov A, Vinogradov L, Virgili T, Vislavicius V, Vodopyanov A, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vranic D, Vrláková J, Wagner B, Wang H, Wang M, Watanabe D, Watanabe Y, Weber M, Weber SG, Weiser DF, Wenzel SC, Wessels JP, Westerhoff U, Whitehead AM, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Williams MCS, Willsher E, Windelband B, Witt WE, Yalcin S, Yamakawa K, Yang P, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang H, Zhang X, Zhang Y, Zhang C, Zhang Z, Zhao C, Zhigareva N, Zhou D, Zhou Y, Zhou Z, Zhu H, Zhu J, Zhu X, Zichichi A, Zimmermann A, Zimmermann MB, Zinovjev G, Zmeskal J, Zou S. D-Meson Azimuthal Anisotropy in Midcentral Pb-Pb Collisions at sqrt[s]_{NN}=5.02 TeV. Phys Rev Lett 2018; 120:102301. [PMID: 29570314 DOI: 10.1103/physrevlett.120.102301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Revised: 11/16/2017] [Indexed: 06/08/2023]
Abstract
The azimuthal anisotropy coefficient v_{2} of prompt D^{0}, D^{+}, D^{*+}, and D_{s}^{+} mesons was measured in midcentral (30%-50% centrality class) Pb-Pb collisions at a center-of-mass energy per nucleon pair sqrt[s_{NN}]=5.02 TeV, with the ALICE detector at the LHC. The D mesons were reconstructed via their hadronic decays at midrapidity, |y|<0.8, in the transverse momentum interval 1<p_{T}<24 GeV/c. The measured D-meson v_{2} has similar values as that of charged pions. The D_{s}^{+} v_{2}, measured for the first time, is found to be compatible with that of nonstrange D mesons. The measurements are compared with theoretical calculations of charm-quark transport in a hydrodynamically expanding medium and have the potential to constrain medium parameters.
Collapse
Affiliation(s)
- S Acharya
- Variable Energy Cyclotron Centre, Kolkata, India
| | - D Adamová
- Nuclear Physics Institute, Academy of Sciences of the Czech Republic, Řež u Prahy, Czech Republic
| | - J Adolfsson
- Division of Experimental High Energy Physics, University of Lund, Lund, Sweden
| | - M M Aggarwal
- Physics Department, Panjab University, Chandigarh, India
| | - G Aglieri Rinella
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Agnello
- Dipartimento DISAT del Politecnico and Sezione INFN, Turin, Italy
| | - N Agrawal
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata, India
| | - N Ahmad
- Department of Physics, Aligarh Muslim University, Aligarh, India
| | - S U Ahn
- Korea Institute of Science and Technology Information, Daejeon, Republic of Korea
| | - S Aiola
- Yale University, New Haven, Connecticut, United States
| | - A Akindinov
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - S N Alam
- Variable Energy Cyclotron Centre, Kolkata, India
| | - J L B Alba
- Sección Física, Departamento de Ciencias, Pontificia Universidad Católica del Perú, Lima, Peru
| | | | - D Aleksandrov
- National Research Centre Kurchatov Institute, Moscow, Russia
| | | | - R Alfaro Molina
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A Alici
- Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi', Rome, Italy
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
- INFN, Sezione di Bologna, Bologna, Italy
| | - A Alkin
- Bogolyubov Institute for Theoretical Physics, Kiev, Ukraine
| | - J Alme
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - T Alt
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - L Altenkamper
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - I Altsybeev
- V. Fock Institute for Physics, St. Petersburg State University, St. Petersburg, Russia
| | | | - C Andrei
- National Institute for Physics and Nuclear Engineering, Bucharest, Romania
| | - D Andreou
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - H A Andrews
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - A Andronic
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - V Anguelov
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - C Anson
- Physics Department, Creighton University, Omaha, Nebraska, United States
| | - T Antičić
- Rudjer Bošković Institute, Zagreb, Croatia
| | | | | | - R Anwar
- University of Houston, Houston, Texas, United States
| | - L Aphecetche
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - H Appelshäuser
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - S Arcelli
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | - R Arnaldi
- INFN, Sezione di Torino, Turin, Italy
| | - O W Arnold
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - I C Arsene
- Department of Physics, University of Oslo, Oslo, Norway
| | - M Arslandok
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - B Audurier
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - A Augustinus
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Averbeck
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - M D Azmi
- Department of Physics, Aligarh Muslim University, Aligarh, India
| | - A Badalà
- INFN, Sezione di Catania, Catania, Italy
| | - Y W Baek
- Inha University, Incheon, Republic of Korea
- Konkuk University, Seoul, Republic of Korea
| | | | - R Bailhache
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - R Bala
- Physics Department, University of Jammu, Jammu, India
| | - A Baldisseri
- IRFU, CEA, Université Paris-Saclay, Saclay, France
| | - M Ball
- Helmholtz-Institut für Strahlen- und Kernphysik, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
| | - R C Baral
- Institute of Physics, Bhubaneswar, India
| | - A M Barbano
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - R Barbera
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Catania, Italy
| | - F Barile
- Dipartimento Interateneo di Fisica 'M. Merlin' and Sezione INFN, Bari, Italy
- INFN, Sezione di Bari, Bari, Italy
| | - L Barioglio
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - G G Barnaföldi
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - L S Barnby
- Nuclear Physics Group, STFC Daresbury Laboratory, Daresbury, United Kingdom
| | - V Barret
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - P Bartalini
- Central China Normal University, Wuhan, China
| | - K Barth
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - E Bartsch
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - M Basile
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | - N Bastid
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - S Basu
- Wayne State University, Detroit, Michigan, United States
| | - G Batigne
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - B Batyunya
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - P C Batzing
- Department of Physics, University of Oslo, Oslo, Norway
| | - I G Bearden
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - H Beck
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - C Bedda
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - N K Behera
- Inha University, Incheon, Republic of Korea
| | - I Belikov
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - F Bellini
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | | | - R Bellwied
- University of Houston, Houston, Texas, United States
| | | | - V Belyaev
- Moscow Engineering Physics Institute, Moscow, Russia
| | - G Bencedi
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - S Beole
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - A Bercuci
- National Institute for Physics and Nuclear Engineering, Bucharest, Romania
| | - Y Berdnikov
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - D Berenyi
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - R A Bertens
- University of Tennessee, Knoxville, Tennessee, United States
| | - D Berzano
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - L Betev
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Bhasin
- Physics Department, University of Jammu, Jammu, India
| | - I R Bhat
- Physics Department, University of Jammu, Jammu, India
| | - A K Bhati
- Physics Department, Panjab University, Chandigarh, India
| | | | - J Bhom
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - L Bianchi
- University of Houston, Houston, Texas, United States
| | - N Bianchi
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
| | - C Bianchin
- Wayne State University, Detroit, Michigan, United States
| | - J Bielčík
- Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, Czech Republic
| | - J Bielčíková
- Nuclear Physics Institute, Academy of Sciences of the Czech Republic, Řež u Prahy, Czech Republic
| | - A Bilandzic
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - G Biro
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - R Biswas
- Bose Institute, Department of Physics and Centre for Astroparticle Physics and Space Science (CAPSS), Kolkata, India
| | - S Biswas
- Bose Institute, Department of Physics and Centre for Astroparticle Physics and Space Science (CAPSS), Kolkata, India
| | - J T Blair
- The University of Texas at Austin, Physics Department, Austin, Texas, United States
| | - D Blau
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - C Blume
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - G Boca
- Università degli Studi di Pavia, Pavia, Italy
| | - F Bock
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A Bogdanov
- Moscow Engineering Physics Institute, Moscow, Russia
| | - L Boldizsár
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - M Bombara
- Faculty of Science, P.J. Šafárik University, Košice, Slovakia
| | - G Bonomi
- Università di Brescia, Brescia, Italy
| | - M Bonora
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Book
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - H Borel
- IRFU, CEA, Université Paris-Saclay, Saclay, France
| | - A Borissov
- Department of Physics, Pusan National University, Pusan, Republic of Korea
| | - M Borri
- University of Liverpool, Liverpool, United Kingdom
| | - E Botta
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - C Bourjau
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - L Bratrud
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - P Braun-Munzinger
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - M Bregant
- Universidade de São Paulo (USP), São Paulo, Brazil
| | - T A Broker
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - M Broz
- Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, Czech Republic
| | - E J Brucken
- Helsinki Institute of Physics (HIP), Helsinki, Finland
| | - E Bruna
- INFN, Sezione di Torino, Turin, Italy
| | - G E Bruno
- Dipartimento Interateneo di Fisica 'M. Merlin' and Sezione INFN, Bari, Italy
| | - D Budnikov
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | - H Buesching
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - S Bufalino
- Dipartimento DISAT del Politecnico and Sezione INFN, Turin, Italy
| | - P Buhler
- Stefan Meyer Institut für Subatomare Physik (SMI), Vienna, Austria
| | - P Buncic
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - O Busch
- University of Tsukuba, Tsukuba, Japan
| | - Z Buthelezi
- iThemba LABS, National Research Foundation, Somerset West, South Africa
| | - J B Butt
- COMSATS Institute of Information Technology (CIIT), Islamabad, Pakistan
| | - J T Buxton
- Department of Physics, Ohio State University, Columbus, Ohio, United States
| | - J Cabala
- Technical University of Košice, Košice, Slovakia
| | - D Caffarri
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Nikhef, Nationaal instituut voor subatomaire fysica, Amsterdam, Netherlands
| | - H Caines
- Yale University, New Haven, Connecticut, United States
| | - A Caliva
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - E Calvo Villar
- Sección Física, Departamento de Ciencias, Pontificia Universidad Católica del Perú, Lima, Peru
| | - P Camerini
- Dipartimento di Fisica dell'Università and Sezione INFN, Trieste, Italy
| | - A A Capon
- Stefan Meyer Institut für Subatomare Physik (SMI), Vienna, Austria
| | - F Carena
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - W Carena
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - F Carnesecchi
- Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi', Rome, Italy
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | | | - A J Castro
- University of Tennessee, Knoxville, Tennessee, United States
| | | | - C Ceballos Sanchez
- Centro de Aplicaciones Tecnológicas y Desarrollo Nuclear (CEADEN), Havana, Cuba
| | - P Cerello
- INFN, Sezione di Torino, Turin, Italy
| | - S Chandra
- Variable Energy Cyclotron Centre, Kolkata, India
| | - B Chang
- University of Jyväskylä, Jyväskylä, Finland
| | - S Chapeland
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M Chartier
- University of Liverpool, Liverpool, United Kingdom
| | - J L Charvet
- IRFU, CEA, Université Paris-Saclay, Saclay, France
| | | | | | - A Chauvin
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - M Cherney
- Physics Department, Creighton University, Omaha, Nebraska, United States
| | - C Cheshkov
- Université de Lyon, Université Lyon 1, CNRS/IN2P3, IPN-Lyon, Villeurbanne, Lyon, France
| | - B Cheynis
- Université de Lyon, Université Lyon 1, CNRS/IN2P3, IPN-Lyon, Villeurbanne, Lyon, France
| | | | - D D Chinellato
- Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
| | - S Cho
- Inha University, Incheon, Republic of Korea
| | - P Chochula
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - K Choi
- Department of Physics, Pusan National University, Pusan, Republic of Korea
| | - M Chojnacki
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - S Choudhury
- Variable Energy Cyclotron Centre, Kolkata, India
| | - T Chowdhury
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - P Christakoglou
- Nikhef, Nationaal instituut voor subatomaire fysica, Amsterdam, Netherlands
| | - C H Christensen
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - P Christiansen
- Division of Experimental High Energy Physics, University of Lund, Lund, Sweden
| | - T Chujo
- University of Tsukuba, Tsukuba, Japan
| | - S U Chung
- Department of Physics, Pusan National University, Pusan, Republic of Korea
| | - C Cicalo
- INFN, Sezione di Cagliari, Cagliari, Italy
| | - L Cifarelli
- Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi', Rome, Italy
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | - F Cindolo
- INFN, Sezione di Bologna, Bologna, Italy
| | - J Cleymans
- Physics Department, University of Cape Town, Cape Town, South Africa
| | - F Colamaria
- Dipartimento Interateneo di Fisica 'M. Merlin' and Sezione INFN, Bari, Italy
| | - D Colella
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
| | - A Collu
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - M Colocci
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | - M Concas
- INFN, Sezione di Torino, Turin, Italy
| | - G Conesa Balbastre
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
| | - Z Conesa Del Valle
- Institut de Physique Nucléaire d'Orsay (IPNO), Université Paris-Sud, CNRS-IN2P3, Orsay, France
| | - M E Connors
- Yale University, New Haven, Connecticut, United States
| | - J G Contreras
- Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, Czech Republic
| | - T M Cormier
- Oak Ridge National Laboratory, Oak Ridge, Tennessee, United States
| | | | | | - P Cortese
- Dipartimento di Scienze e Innovazione Tecnologica dell'Università del Piemonte Orientale and INFN Sezione di Torino, Alessandria, Italy
| | | | - F Costa
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Costanza
- Università degli Studi di Pavia, Pavia, Italy
| | - J Crkovská
- Institut de Physique Nucléaire d'Orsay (IPNO), Université Paris-Sud, CNRS-IN2P3, Orsay, France
| | - P Crochet
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - E Cuautle
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - L Cunqueiro
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - T Dahms
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - A Dainese
- INFN, Sezione di Padova, Padova, Italy
| | - M C Danisch
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A Danu
- Institute of Space Science (ISS), Bucharest, Romania
| | - D Das
- Saha Institute of Nuclear Physics, Kolkata, India
| | - I Das
- Saha Institute of Nuclear Physics, Kolkata, India
| | - S Das
- Bose Institute, Department of Physics and Centre for Astroparticle Physics and Space Science (CAPSS), Kolkata, India
| | - A Dash
- National Institute of Science Education and Research, HBNI, Jatni, India
| | - S Dash
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - S De
- Indian Institute of Technology Indore, Indore, India
- Universidade de São Paulo (USP), São Paulo, Brazil
| | - A De Caro
- Dipartimento di Fisica 'E.R. Caianiello' dell'Università and Gruppo Collegato INFN, Salerno, Italy
| | | | - C de Conti
- Universidade de São Paulo (USP), São Paulo, Brazil
| | - J de Cuveland
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - A De Falco
- Dipartimento di Fisica dell'Università and Sezione INFN, Cagliari, Italy
| | - D De Gruttola
- Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi', Rome, Italy
- Dipartimento di Fisica 'E.R. Caianiello' dell'Università and Gruppo Collegato INFN, Salerno, Italy
| | | | - S De Pasquale
- Dipartimento di Fisica 'E.R. Caianiello' dell'Università and Gruppo Collegato INFN, Salerno, Italy
| | - R D De Souza
- Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
| | | | - A Deisting
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - A Deloff
- National Centre for Nuclear Studies, Warsaw, Poland
| | - C Deplano
- Nikhef, Nationaal instituut voor subatomaire fysica, Amsterdam, Netherlands
| | - P Dhankher
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - D Di Bari
- Dipartimento Interateneo di Fisica 'M. Merlin' and Sezione INFN, Bari, Italy
| | - A Di Mauro
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P Di Nezza
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
| | | | - M A Diaz Corchero
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - T Dietel
- Physics Department, University of Cape Town, Cape Town, South Africa
| | - P Dillenseger
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - R Divià
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Ø Djuvsland
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - A Dobrin
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - B Dönigus
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - O Dordic
- Department of Physics, University of Oslo, Oslo, Norway
| | - L V V Doremalen
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - A K Dubey
- Variable Energy Cyclotron Centre, Kolkata, India
| | - A Dubla
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - L Ducroux
- Université de Lyon, Université Lyon 1, CNRS/IN2P3, IPN-Lyon, Villeurbanne, Lyon, France
| | - A K Duggal
- Physics Department, Panjab University, Chandigarh, India
| | - P Dupieux
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - R J Ehlers
- Yale University, New Haven, Connecticut, United States
| | - D Elia
- INFN, Sezione di Bari, Bari, Italy
| | - E Endress
- Sección Física, Departamento de Ciencias, Pontificia Universidad Católica del Perú, Lima, Peru
| | - H Engel
- Institut für Informatik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - E Epple
- Yale University, New Haven, Connecticut, United States
| | - B Erazmus
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - F Erhardt
- Physics department, Faculty of science, University of Zagreb, Zagreb, Croatia
| | - B Espagnon
- Institut de Physique Nucléaire d'Orsay (IPNO), Université Paris-Sud, CNRS-IN2P3, Orsay, France
| | - S Esumi
- University of Tsukuba, Tsukuba, Japan
| | - G Eulisse
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Eum
- Department of Physics, Pusan National University, Pusan, Republic of Korea
| | - D Evans
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - S Evdokimov
- SSC IHEP of NRC Kurchatov institute, Protvino, Russia
| | - L Fabbietti
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - J Faivre
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
| | - A Fantoni
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
| | - M Fasel
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
- Oak Ridge National Laboratory, Oak Ridge, Tennessee, United States
| | - L Feldkamp
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | | | - G Feofilov
- V. Fock Institute for Physics, St. Petersburg State University, St. Petersburg, Russia
| | - J Ferencei
- Nuclear Physics Institute, Academy of Sciences of the Czech Republic, Řež u Prahy, Czech Republic
| | | | - E G Ferreiro
- Departamento de Física de Partículas and IGFAE, Universidad de Santiago de Compostela, Santiago de Compostela, Spain
| | - A Ferretti
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - A Festanti
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Padova, Italy
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - V J G Feuillard
- IRFU, CEA, Université Paris-Saclay, Saclay, France
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - J Figiel
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | | | - S Filchagin
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | - D Finogeev
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - F M Fionda
- Department of Physics and Technology, University of Bergen, Bergen, Norway
- Dipartimento di Fisica dell'Università and Sezione INFN, Cagliari, Italy
| | - E M Fiore
- Dipartimento Interateneo di Fisica 'M. Merlin' and Sezione INFN, Bari, Italy
| | - M Floris
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Foertsch
- iThemba LABS, National Research Foundation, Somerset West, South Africa
| | - P Foka
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - S Fokin
- National Research Centre Kurchatov Institute, Moscow, Russia
| | | | - A Francescon
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Francisco
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - U Frankenfeld
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - G G Fronze
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - U Fuchs
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C Furget
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
| | - A Furs
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - M Fusco Girard
- Dipartimento di Fisica 'E.R. Caianiello' dell'Università and Gruppo Collegato INFN, Salerno, Italy
| | - J J Gaardhøje
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - M Gagliardi
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - A M Gago
- Sección Física, Departamento de Ciencias, Pontificia Universidad Católica del Perú, Lima, Peru
| | - K Gajdosova
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - M Gallio
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - C D Galvan
- Universidad Autónoma de Sinaloa, Culiacán, Mexico
| | - P Ganoti
- National and Kapodistrian University of Athens, Physics Department, Athens, Greece
| | - C Gao
- Central China Normal University, Wuhan, China
| | - C Garabatos
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - E Garcia-Solis
- Chicago State University, Chicago, Illinois, United States
| | - K Garg
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Catania, Italy
| | - C Gargiulo
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P Gasik
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - E F Gauger
- The University of Texas at Austin, Physics Department, Austin, Texas, United States
| | - M B Gay Ducati
- Instituto de Física, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
| | - M Germain
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - J Ghosh
- Saha Institute of Nuclear Physics, Kolkata, India
| | - P Ghosh
- Variable Energy Cyclotron Centre, Kolkata, India
| | - S K Ghosh
- Bose Institute, Department of Physics and Centre for Astroparticle Physics and Space Science (CAPSS), Kolkata, India
| | - P Gianotti
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
| | - P Giubellino
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- INFN, Sezione di Torino, Turin, Italy
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - P Giubilato
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Padova, Italy
| | - E Gladysz-Dziadus
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - P Glässel
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - D M Goméz Coral
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A Gomez Ramirez
- Institut für Informatik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - A S Gonzalez
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - V Gonzalez
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - P González-Zamora
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - S Gorbunov
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - L Görlich
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - S Gotovac
- Technical University of Split FESB, Split, Croatia
| | - V Grabski
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | | | - K L Graham
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - L Greiner
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - A Grelli
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - C Grigoras
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - V Grigoriev
- Moscow Engineering Physics Institute, Moscow, Russia
| | - A Grigoryan
- A.I. Alikhanyan National Science Laboratory (Yerevan Physics Institute) Foundation, Yerevan, Armenia
| | - S Grigoryan
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - N Grion
- INFN, Sezione di Trieste, Trieste, Italy
| | - J M Gronefeld
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - F Grosa
- Dipartimento DISAT del Politecnico and Sezione INFN, Turin, Italy
| | | | - R Grosso
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - L Gruber
- Stefan Meyer Institut für Subatomare Physik (SMI), Vienna, Austria
| | - F Guber
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - R Guernane
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
| | - B Guerzoni
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | - K Gulbrandsen
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - T Gunji
- University of Tokyo, Tokyo, Japan
| | - A Gupta
- Physics Department, University of Jammu, Jammu, India
| | - R Gupta
- Physics Department, University of Jammu, Jammu, India
| | - I B Guzman
- Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - R Haake
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C Hadjidakis
- Institut de Physique Nucléaire d'Orsay (IPNO), Université Paris-Sud, CNRS-IN2P3, Orsay, France
| | - H Hamagaki
- Nagasaki Institute of Applied Science, Nagasaki, Japan
- University of Tokyo, Tokyo, Japan
| | - G Hamar
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - J C Hamon
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - M R Haque
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - J W Harris
- Yale University, New Haven, Connecticut, United States
| | - A Harton
- Chicago State University, Chicago, Illinois, United States
| | - H Hassan
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
| | - D Hatzifotiadou
- Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi', Rome, Italy
- INFN, Sezione di Bologna, Bologna, Italy
| | | | - S T Heckel
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - E Hellbär
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - H Helstrup
- Faculty of Engineering, Bergen University College, Bergen, Norway
| | - A Herghelegiu
- National Institute for Physics and Nuclear Engineering, Bucharest, Romania
| | - G Herrera Corral
- Centro de Investigación y de Estudios Avanzados (CINVESTAV), Mexico City and Mérida, Mexico
| | - F Herrmann
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - B A Hess
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - K F Hetland
- Faculty of Engineering, Bergen University College, Bergen, Norway
| | - H Hillemanns
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C Hills
- University of Liverpool, Liverpool, United Kingdom
| | - B Hippolyte
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - J Hladky
- Institute of Physics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - B Hohlweger
- Physik Department, Technische Universität München, Munich, Germany
| | - D Horak
- Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, Czech Republic
| | - S Hornung
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - R Hosokawa
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
- University of Tsukuba, Tsukuba, Japan
| | - P Hristov
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C Hughes
- University of Tennessee, Knoxville, Tennessee, United States
| | - T J Humanic
- Department of Physics, Ohio State University, Columbus, Ohio, United States
| | - N Hussain
- Gauhati University, Department of Physics, Guwahati, India
| | - T Hussain
- Department of Physics, Aligarh Muslim University, Aligarh, India
| | - D Hutter
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - D S Hwang
- Department of Physics, Sejong University, Seoul, Republic of Korea
| | - S A Iga Buitron
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - R Ilkaev
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | - M Inaba
- University of Tsukuba, Tsukuba, Japan
| | - M Ippolitov
- Moscow Engineering Physics Institute, Moscow, Russia
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - M Irfan
- Department of Physics, Aligarh Muslim University, Aligarh, India
| | - V Isakov
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - M Ivanov
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - V Ivanov
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - V Izucheev
- SSC IHEP of NRC Kurchatov institute, Protvino, Russia
| | - B Jacak
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - N Jacazio
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | - P M Jacobs
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - M B Jadhav
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - J Jadlovsky
- Technical University of Košice, Košice, Slovakia
| | - S Jaelani
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - C Jahnke
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
| | | | - M A Janik
- Warsaw University of Technology, Warsaw, Poland
| | | | - C Jena
- National Institute of Science Education and Research, HBNI, Jatni, India
| | - S Jena
- University of Houston, Houston, Texas, United States
| | - M Jercic
- Physics department, Faculty of science, University of Zagreb, Zagreb, Croatia
| | - R T Jimenez Bustamante
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - P G Jones
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - A Jusko
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - P Kalinak
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
| | - A Kalweit
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J H Kang
- Yonsei University, Seoul, Republic of Korea
| | - V Kaplin
- Moscow Engineering Physics Institute, Moscow, Russia
| | - S Kar
- Variable Energy Cyclotron Centre, Kolkata, India
| | | | - O Karavichev
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - T Karavicheva
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - L Karayan
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - P Karczmarczyk
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - E Karpechev
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - U Kebschull
- Institut für Informatik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - R Keidel
- Zentrum für Technologietransfer und Telekommunikation (ZTT), Fachhochschule Worms, Worms, Germany
| | - D L D Keijdener
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - M Keil
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - B Ketzer
- Helmholtz-Institut für Strahlen- und Kernphysik, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
| | - Z Khabanova
- Nikhef, Nationaal instituut voor subatomaire fysica, Amsterdam, Netherlands
| | - P Khan
- Saha Institute of Nuclear Physics, Kolkata, India
| | - S A Khan
- Variable Energy Cyclotron Centre, Kolkata, India
| | - A Khanzadeev
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - Y Kharlov
- SSC IHEP of NRC Kurchatov institute, Protvino, Russia
| | - A Khatun
- Department of Physics, Aligarh Muslim University, Aligarh, India
| | - A Khuntia
- Indian Institute of Technology Indore, Indore, India
| | - M M Kielbowicz
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - B Kileng
- Faculty of Engineering, Bergen University College, Bergen, Norway
| | - B Kim
- University of Tsukuba, Tsukuba, Japan
| | - D Kim
- Yonsei University, Seoul, Republic of Korea
| | - D J Kim
- University of Jyväskylä, Jyväskylä, Finland
| | - H Kim
- Yonsei University, Seoul, Republic of Korea
| | - J S Kim
- Gangneung-Wonju National University, Gangneung, Republic of Korea
| | - J Kim
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - M Kim
- Inha University, Incheon, Republic of Korea
| | - M Kim
- Yonsei University, Seoul, Republic of Korea
| | - S Kim
- Department of Physics, Sejong University, Seoul, Republic of Korea
| | - T Kim
- Yonsei University, Seoul, Republic of Korea
| | - S Kirsch
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - I Kisel
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - S Kiselev
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - A Kisiel
- Warsaw University of Technology, Warsaw, Poland
| | - G Kiss
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - J L Klay
- California Polytechnic State University, San Luis Obispo, California, United States
| | - C Klein
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - J Klein
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - C Klein-Bösing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - S Klewin
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A Kluge
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M L Knichel
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - A G Knospe
- University of Houston, Houston, Texas, United States
| | - C Kobdaj
- Suranaree University of Technology, Nakhon Ratchasima, Thailand
| | - M Kofarago
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - T Kollegger
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - A Kolojvari
- V. Fock Institute for Physics, St. Petersburg State University, St. Petersburg, Russia
| | - V Kondratiev
- V. Fock Institute for Physics, St. Petersburg State University, St. Petersburg, Russia
| | - N Kondratyeva
- Moscow Engineering Physics Institute, Moscow, Russia
| | - E Kondratyuk
- SSC IHEP of NRC Kurchatov institute, Protvino, Russia
| | - A Konevskikh
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - M Konyushikhin
- Wayne State University, Detroit, Michigan, United States
| | - M Kopcik
- Technical University of Košice, Košice, Slovakia
| | - M Kour
- Physics Department, University of Jammu, Jammu, India
| | - C Kouzinopoulos
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - O Kovalenko
- National Centre for Nuclear Studies, Warsaw, Poland
| | - V Kovalenko
- V. Fock Institute for Physics, St. Petersburg State University, St. Petersburg, Russia
| | - M Kowalski
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | | | - I Králik
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
| | - A Kravčáková
- Faculty of Science, P.J. Šafárik University, Košice, Slovakia
| | - M Krivda
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - F Krizek
- Nuclear Physics Institute, Academy of Sciences of the Czech Republic, Řež u Prahy, Czech Republic
| | - E Kryshen
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - M Krzewicki
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - A M Kubera
- Department of Physics, Ohio State University, Columbus, Ohio, United States
| | - V Kučera
- Nuclear Physics Institute, Academy of Sciences of the Czech Republic, Řež u Prahy, Czech Republic
| | - C Kuhn
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - P G Kuijer
- Nikhef, Nationaal instituut voor subatomaire fysica, Amsterdam, Netherlands
| | - A Kumar
- Physics Department, University of Jammu, Jammu, India
| | - J Kumar
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - L Kumar
- Physics Department, Panjab University, Chandigarh, India
| | - S Kumar
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - S Kundu
- National Institute of Science Education and Research, HBNI, Jatni, India
| | - P Kurashvili
- National Centre for Nuclear Studies, Warsaw, Poland
| | - A Kurepin
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - A B Kurepin
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - A Kuryakin
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | - S Kushpil
- Nuclear Physics Institute, Academy of Sciences of the Czech Republic, Řež u Prahy, Czech Republic
| | - M J Kweon
- Inha University, Incheon, Republic of Korea
| | - Y Kwon
- Yonsei University, Seoul, Republic of Korea
| | - S L La Pointe
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - P La Rocca
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Catania, Italy
| | | | - Y S Lai
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - I Lakomov
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Langoy
- Faculty of Technology, Buskerud and Vestfold University College, Tonsberg, Norway
| | - K Lapidus
- Yale University, New Haven, Connecticut, United States
| | - C Lara
- Institut für Informatik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - A Lardeux
- Department of Physics, University of Oslo, Oslo, Norway
- IRFU, CEA, Université Paris-Saclay, Saclay, France
| | - A Lattuca
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - E Laudi
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Lavicka
- Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, Czech Republic
| | - L Lazaridis
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Lea
- Dipartimento di Fisica dell'Università and Sezione INFN, Trieste, Italy
| | - L Leardini
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - S Lee
- Yonsei University, Seoul, Republic of Korea
| | - F Lehas
- Nikhef, Nationaal instituut voor subatomaire fysica, Amsterdam, Netherlands
| | - S Lehner
- Stefan Meyer Institut für Subatomare Physik (SMI), Vienna, Austria
| | - J Lehrbach
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - R C Lemmon
- Nuclear Physics Group, STFC Daresbury Laboratory, Daresbury, United Kingdom
| | - V Lenti
- INFN, Sezione di Bari, Bari, Italy
| | - E Leogrande
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | | | - P Lévai
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - S Li
- Central China Normal University, Wuhan, China
| | - X Li
- China Institute of Atomic Energy, Beijing, China
| | - J Lien
- Faculty of Technology, Buskerud and Vestfold University College, Tonsberg, Norway
| | - R Lietava
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - B Lim
- Department of Physics, Pusan National University, Pusan, Republic of Korea
| | - S Lindal
- Department of Physics, University of Oslo, Oslo, Norway
| | - V Lindenstruth
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - S W Lindsay
- University of Liverpool, Liverpool, United Kingdom
| | - C Lippmann
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - M A Lisa
- Department of Physics, Ohio State University, Columbus, Ohio, United States
| | | | - H M Ljunggren
- Division of Experimental High Energy Physics, University of Lund, Lund, Sweden
| | - W J Llope
- Wayne State University, Detroit, Michigan, United States
| | - D F Lodato
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - P I Loenne
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - V Loginov
- Moscow Engineering Physics Institute, Moscow, Russia
| | - C Loizides
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - P Loncar
- Technical University of Split FESB, Split, Croatia
| | - X Lopez
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - E López Torres
- Centro de Aplicaciones Tecnológicas y Desarrollo Nuclear (CEADEN), Havana, Cuba
| | - A Lowe
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - P Luettig
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - J R Luhder
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - M Lunardon
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Padova, Italy
| | - G Luparello
- Dipartimento di Fisica dell'Università and Sezione INFN, Trieste, Italy
- INFN, Sezione di Trieste, Trieste, Italy
| | - M Lupi
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - T H Lutz
- Yale University, New Haven, Connecticut, United States
| | - A Maevskaya
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - M Mager
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Mahajan
- Physics Department, University of Jammu, Jammu, India
| | - S M Mahmood
- Department of Physics, University of Oslo, Oslo, Norway
| | - A Maire
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - R D Majka
- Yale University, New Haven, Connecticut, United States
| | - M Malaev
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - L Malinina
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - D Mal'Kevich
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - P Malzacher
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - A Mamonov
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | - V Manko
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - F Manso
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | | | - Y Mao
- Central China Normal University, Wuhan, China
| | - M Marchisone
- iThemba LABS, National Research Foundation, Somerset West, South Africa
- University of the Witwatersrand, Johannesburg, South Africa
| | - J Mareš
- Institute of Physics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - G V Margagliotti
- Dipartimento di Fisica dell'Università and Sezione INFN, Trieste, Italy
| | - A Margotti
- INFN, Sezione di Bologna, Bologna, Italy
| | - J Margutti
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - A Marín
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - C Markert
- The University of Texas at Austin, Physics Department, Austin, Texas, United States
| | - M Marquard
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - N A Martin
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - P Martinengo
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J A L Martinez
- Institut für Informatik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - M I Martínez
- Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - G Martínez García
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | | | - A Mas
- Universidade de São Paulo (USP), São Paulo, Brazil
| | - S Masciocchi
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - M Masera
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - A Masoni
- INFN, Sezione di Cagliari, Cagliari, Italy
| | - E Masson
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | | | - A M Mathis
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - A Matyja
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
- University of Tennessee, Knoxville, Tennessee, United States
| | - C Mayer
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - J Mazer
- University of Tennessee, Knoxville, Tennessee, United States
| | - M Mazzilli
- Dipartimento Interateneo di Fisica 'M. Merlin' and Sezione INFN, Bari, Italy
| | | | - F Meddi
- Dipartimento di Fisica dell'Università 'La Sapienza' and Sezione INFN, Rome, Italy
| | - Y Melikyan
- Moscow Engineering Physics Institute, Moscow, Russia
| | - A Menchaca-Rocha
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - E Meninno
- Dipartimento di Fisica 'E.R. Caianiello' dell'Università and Gruppo Collegato INFN, Salerno, Italy
| | - J Mercado Pérez
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - M Meres
- Faculty of Mathematics, Physics and Informatics, Comenius University, Bratislava, Slovakia
| | - S Mhlanga
- Physics Department, University of Cape Town, Cape Town, South Africa
| | - Y Miake
- University of Tsukuba, Tsukuba, Japan
| | | | - D Mihaylov
- Physik Department, Technische Universität München, Munich, Germany
| | - D L Mihaylov
- Physik Department, Technische Universität München, Munich, Germany
| | - K Mikhaylov
- Institute for Theoretical and Experimental Physics, Moscow, Russia
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - L Milano
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - J Milosevic
- Department of Physics, University of Oslo, Oslo, Norway
| | - A Mischke
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - A N Mishra
- Indian Institute of Technology Indore, Indore, India
| | - D Miśkowiec
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - J Mitra
- Variable Energy Cyclotron Centre, Kolkata, India
| | - C M Mitu
- Institute of Space Science (ISS), Bucharest, Romania
| | - N Mohammadi
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - B Mohanty
- National Institute of Science Education and Research, HBNI, Jatni, India
| | - M Mohisin Khan
- Department of Physics, Aligarh Muslim University, Aligarh, India
| | - E Montes
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - D A Moreira De Godoy
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - L A P Moreno
- Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - S Moretto
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Padova, Italy
| | - A Morreale
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - A Morsch
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - V Muccifora
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
| | - E Mudnic
- Technical University of Split FESB, Split, Croatia
| | - D Mühlheim
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - S Muhuri
- Variable Energy Cyclotron Centre, Kolkata, India
| | - M Mukherjee
- Bose Institute, Department of Physics and Centre for Astroparticle Physics and Space Science (CAPSS), Kolkata, India
| | - J D Mulligan
- Yale University, New Haven, Connecticut, United States
| | - M G Munhoz
- Universidade de São Paulo (USP), São Paulo, Brazil
| | - K Münning
- Helmholtz-Institut für Strahlen- und Kernphysik, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
| | - R H Munzer
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | | | - S Murray
- iThemba LABS, National Research Foundation, Somerset West, South Africa
| | - L Musa
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Musinsky
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
| | - C J Myers
- University of Houston, Houston, Texas, United States
| | - J W Myrcha
- Warsaw University of Technology, Warsaw, Poland
| | - B Naik
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - R Nair
- National Centre for Nuclear Studies, Warsaw, Poland
| | - B K Nandi
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - R Nania
- Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi', Rome, Italy
- INFN, Sezione di Bologna, Bologna, Italy
| | - E Nappi
- INFN, Sezione di Bari, Bari, Italy
| | - A Narayan
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - M U Naru
- COMSATS Institute of Information Technology (CIIT), Islamabad, Pakistan
| | | | - C Nattrass
- University of Tennessee, Knoxville, Tennessee, United States
| | - S R Navarro
- Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - K Nayak
- National Institute of Science Education and Research, HBNI, Jatni, India
| | - R Nayak
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - T K Nayak
- Variable Energy Cyclotron Centre, Kolkata, India
| | - S Nazarenko
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | - A Nedosekin
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | | | - L Nellen
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - S V Nesbo
- Faculty of Engineering, Bergen University College, Bergen, Norway
| | - F Ng
- University of Houston, Houston, Texas, United States
| | - M Nicassio
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - M Niculescu
- Institute of Space Science (ISS), Bucharest, Romania
| | - J Niedziela
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Warsaw University of Technology, Warsaw, Poland
| | - B S Nielsen
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - S Nikolaev
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - S Nikulin
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - V Nikulin
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | | | - F Noferini
- Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi', Rome, Italy
- INFN, Sezione di Bologna, Bologna, Italy
| | - P Nomokonov
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - G Nooren
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - J C C Noris
- Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - J Norman
- University of Liverpool, Liverpool, United Kingdom
| | - A Nyanin
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - J Nystrand
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - H Oeschler
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - S Oh
- Yale University, New Haven, Connecticut, United States
| | - A Ohlson
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - T Okubo
- Hiroshima University, Hiroshima, Japan
| | - L Olah
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - J Oleniacz
- Warsaw University of Technology, Warsaw, Poland
| | | | - M H Oliver
- Yale University, New Haven, Connecticut, United States
| | - J Onderwaater
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | | | - R Orava
- Helsinki Institute of Physics (HIP), Helsinki, Finland
| | - M Oravec
- Technical University of Košice, Košice, Slovakia
| | - A Ortiz Velasquez
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A Oskarsson
- Division of Experimental High Energy Physics, University of Lund, Lund, Sweden
| | - J Otwinowski
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - K Oyama
- Nagasaki Institute of Applied Science, Nagasaki, Japan
| | - Y Pachmayer
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - V Pacik
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - D Pagano
- Università di Brescia, Brescia, Italy
| | - P Pagano
- Dipartimento di Fisica 'E.R. Caianiello' dell'Università and Gruppo Collegato INFN, Salerno, Italy
| | - G Paić
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - P Palni
- Central China Normal University, Wuhan, China
| | - J Pan
- Wayne State University, Detroit, Michigan, United States
| | - A K Pandey
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - S Panebianco
- IRFU, CEA, Université Paris-Saclay, Saclay, France
| | - V Papikyan
- A.I. Alikhanyan National Science Laboratory (Yerevan Physics Institute) Foundation, Yerevan, Armenia
| | | | - P Pareek
- Indian Institute of Technology Indore, Indore, India
| | - J Park
- Inha University, Incheon, Republic of Korea
| | - S Parmar
- Physics Department, Panjab University, Chandigarh, India
| | - A Passfeld
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - S P Pathak
- University of Houston, Houston, Texas, United States
| | | | - R N Patra
- Variable Energy Cyclotron Centre, Kolkata, India
| | - B Paul
- INFN, Sezione di Torino, Turin, Italy
| | - H Pei
- Central China Normal University, Wuhan, China
| | - T Peitzmann
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - X Peng
- Central China Normal University, Wuhan, China
| | - L G Pereira
- Instituto de Física, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
| | | | - D Peresunko
- Moscow Engineering Physics Institute, Moscow, Russia
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - E Perez Lezama
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - V Peskov
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - Y Pestov
- Budker Institute for Nuclear Physics, Novosibirsk, Russia
| | - V Petráček
- Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, Czech Republic
| | - V Petrov
- SSC IHEP of NRC Kurchatov institute, Protvino, Russia
| | - M Petrovici
- National Institute for Physics and Nuclear Engineering, Bucharest, Romania
| | - C Petta
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Catania, Italy
| | - R P Pezzi
- Instituto de Física, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
| | - S Piano
- INFN, Sezione di Trieste, Trieste, Italy
| | - M Pikna
- Faculty of Mathematics, Physics and Informatics, Comenius University, Bratislava, Slovakia
| | - P Pillot
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - L O D L Pimentel
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - O Pinazza
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- INFN, Sezione di Bologna, Bologna, Italy
| | - L Pinsky
- University of Houston, Houston, Texas, United States
| | | | - M Płoskoń
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - M Planinic
- Physics department, Faculty of science, University of Zagreb, Zagreb, Croatia
| | - F Pliquett
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - J Pluta
- Warsaw University of Technology, Warsaw, Poland
| | - S Pochybova
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | | | - M G Poghosyan
- Oak Ridge National Laboratory, Oak Ridge, Tennessee, United States
| | | | - N Poljak
- Physics department, Faculty of science, University of Zagreb, Zagreb, Croatia
| | - W Poonsawat
- Suranaree University of Technology, Nakhon Ratchasima, Thailand
| | - A Pop
- National Institute for Physics and Nuclear Engineering, Bucharest, Romania
| | - H Poppenborg
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - S Porteboeuf-Houssais
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - J Porter
- Lawrence Berkeley National Laboratory, Berkeley, California, United States
| | - V Pozdniakov
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - S K Prasad
- Bose Institute, Department of Physics and Centre for Astroparticle Physics and Space Science (CAPSS), Kolkata, India
| | | | - F Prino
- INFN, Sezione di Torino, Turin, Italy
| | - C A Pruneau
- Wayne State University, Detroit, Michigan, United States
| | - I Pshenichnov
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - M Puccio
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - G Puddu
- Dipartimento di Fisica dell'Università and Sezione INFN, Cagliari, Italy
| | - P Pujahari
- Wayne State University, Detroit, Michigan, United States
| | - V Punin
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | - J Putschke
- Wayne State University, Detroit, Michigan, United States
| | | | - S Raha
- Bose Institute, Department of Physics and Centre for Astroparticle Physics and Space Science (CAPSS), Kolkata, India
| | - S Rajput
- Physics Department, University of Jammu, Jammu, India
| | - J Rak
- University of Jyväskylä, Jyväskylä, Finland
| | | | - L Ramello
- Dipartimento di Scienze e Innovazione Tecnologica dell'Università del Piemonte Orientale and INFN Sezione di Torino, Alessandria, Italy
| | - F Rami
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - D B Rana
- University of Houston, Houston, Texas, United States
| | - R Raniwala
- Physics Department, University of Rajasthan, Jaipur, India
| | - S Raniwala
- Physics Department, University of Rajasthan, Jaipur, India
| | - S S Räsänen
- Helsinki Institute of Physics (HIP), Helsinki, Finland
| | - B T Rascanu
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - D Rathee
- Physics Department, Panjab University, Chandigarh, India
| | - V Ratza
- Helmholtz-Institut für Strahlen- und Kernphysik, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
| | - I Ravasenga
- Dipartimento DISAT del Politecnico and Sezione INFN, Turin, Italy
| | - K F Read
- Oak Ridge National Laboratory, Oak Ridge, Tennessee, United States
- University of Tennessee, Knoxville, Tennessee, United States
| | - K Redlich
- National Centre for Nuclear Studies, Warsaw, Poland
| | - A Rehman
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - P Reichelt
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - F Reidt
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - X Ren
- Central China Normal University, Wuhan, China
| | - R Renfordt
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - A R Reolon
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Reshetin
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - K Reygers
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - V Riabov
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - R A Ricci
- INFN, Laboratori Nazionali di Legnaro, Legnaro, Italy
| | - T Richert
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - M Richter
- Department of Physics, University of Oslo, Oslo, Norway
| | - P Riedler
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - W Riegler
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - F Riggi
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Catania, Italy
| | - C Ristea
- Institute of Space Science (ISS), Bucharest, Romania
| | | | - K Røed
- Department of Physics, University of Oslo, Oslo, Norway
| | - E Rogochaya
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - D Rohr
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - D Röhrich
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - P S Rokita
- Warsaw University of Technology, Warsaw, Poland
| | - F Ronchetti
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
| | - E D Rosas
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - P Rosnet
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - A Rossi
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Padova, Italy
- INFN, Sezione di Padova, Padova, Italy
| | - A Rotondi
- Università degli Studi di Pavia, Pavia, Italy
| | - F Roukoutakis
- National and Kapodistrian University of Athens, Physics Department, Athens, Greece
| | - A Roy
- Indian Institute of Technology Indore, Indore, India
| | - C Roy
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - P Roy
- Saha Institute of Nuclear Physics, Kolkata, India
| | - A J Rubio Montero
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - O V Rueda
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - R Rui
- Dipartimento di Fisica dell'Università and Sezione INFN, Trieste, Italy
| | - B Rumyantsev
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - A Rustamov
- National Nuclear Research Center, Baku, Azerbaijan
| | - E Ryabinkin
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - Y Ryabov
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - A Rybicki
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - S Saarinen
- Helsinki Institute of Physics (HIP), Helsinki, Finland
| | - S Sadhu
- Variable Energy Cyclotron Centre, Kolkata, India
| | - S Sadovsky
- SSC IHEP of NRC Kurchatov institute, Protvino, Russia
| | - K Šafařík
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S K Saha
- Variable Energy Cyclotron Centre, Kolkata, India
| | - B Sahlmuller
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - B Sahoo
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - P Sahoo
- Indian Institute of Technology Indore, Indore, India
| | - R Sahoo
- Indian Institute of Technology Indore, Indore, India
| | - S Sahoo
- Institute of Physics, Bhubaneswar, India
| | - P K Sahu
- Institute of Physics, Bhubaneswar, India
| | - J Saini
- Variable Energy Cyclotron Centre, Kolkata, India
| | - S Sakai
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
- University of Tsukuba, Tsukuba, Japan
| | - M A Saleh
- Wayne State University, Detroit, Michigan, United States
| | - J Salzwedel
- Department of Physics, Ohio State University, Columbus, Ohio, United States
| | - S Sambyal
- Physics Department, University of Jammu, Jammu, India
| | - V Samsonov
- Moscow Engineering Physics Institute, Moscow, Russia
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - A Sandoval
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - D Sarkar
- Variable Energy Cyclotron Centre, Kolkata, India
| | - N Sarkar
- Variable Energy Cyclotron Centre, Kolkata, India
| | - P Sarma
- Gauhati University, Department of Physics, Guwahati, India
| | - M H P Sas
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | | | - F Scarlassara
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Padova, Italy
| | | | - H S Scheid
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - C Schiaua
- National Institute for Physics and Nuclear Engineering, Bucharest, Romania
| | - R Schicker
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - C Schmidt
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - H R Schmidt
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - M O Schmidt
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - M Schmidt
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - N V Schmidt
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
- Oak Ridge National Laboratory, Oak Ridge, Tennessee, United States
| | - S Schuchmann
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - J Schukraft
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Y Schutz
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - K Schwarz
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - K Schweda
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - G Scioli
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | | | - R Scott
- University of Tennessee, Knoxville, Tennessee, United States
| | - M Šefčík
- Faculty of Science, P.J. Šafárik University, Košice, Slovakia
| | - J E Seger
- Physics Department, Creighton University, Omaha, Nebraska, United States
| | | | | | - I Selyuzhenkov
- Moscow Engineering Physics Institute, Moscow, Russia
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - K Senosi
- iThemba LABS, National Research Foundation, Somerset West, South Africa
| | - S Senyukov
- Bogolyubov Institute for Theoretical Physics, Kiev, Ukraine
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France, Strasbourg, France
| | - E Serradilla
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
- Instituto de Física, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - P Sett
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - A Sevcenco
- Institute of Space Science (ISS), Bucharest, Romania
| | - A Shabanov
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - A Shabetai
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - R Shahoyan
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - W Shaikh
- Saha Institute of Nuclear Physics, Kolkata, India
| | - A Shangaraev
- SSC IHEP of NRC Kurchatov institute, Protvino, Russia
| | - A Sharma
- Physics Department, Panjab University, Chandigarh, India
| | - A Sharma
- Physics Department, University of Jammu, Jammu, India
| | - M Sharma
- Physics Department, University of Jammu, Jammu, India
| | - M Sharma
- Physics Department, University of Jammu, Jammu, India
| | - N Sharma
- Physics Department, Panjab University, Chandigarh, India
- University of Tennessee, Knoxville, Tennessee, United States
| | - A I Sheikh
- Variable Energy Cyclotron Centre, Kolkata, India
| | - K Shigaki
- Hiroshima University, Hiroshima, Japan
| | - Q Shou
- Central China Normal University, Wuhan, China
| | - K Shtejer
- Centro de Aplicaciones Tecnológicas y Desarrollo Nuclear (CEADEN), Havana, Cuba
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - Y Sibiriak
- National Research Centre Kurchatov Institute, Moscow, Russia
| | | | - K M Sielewicz
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - D Silvermyr
- Division of Experimental High Energy Physics, University of Lund, Lund, Sweden
| | - C Silvestre
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
| | - G Simatovic
- Physics department, Faculty of science, University of Zagreb, Zagreb, Croatia
| | - G Simonetti
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Singaraju
- Variable Energy Cyclotron Centre, Kolkata, India
| | - R Singh
- National Institute of Science Education and Research, HBNI, Jatni, India
| | - V Singhal
- Variable Energy Cyclotron Centre, Kolkata, India
| | - T Sinha
- Saha Institute of Nuclear Physics, Kolkata, India
| | - B Sitar
- Faculty of Mathematics, Physics and Informatics, Comenius University, Bratislava, Slovakia
| | - M Sitta
- Dipartimento di Scienze e Innovazione Tecnologica dell'Università del Piemonte Orientale and INFN Sezione di Torino, Alessandria, Italy
| | - T B Skaali
- Department of Physics, University of Oslo, Oslo, Norway
| | - M Slupecki
- University of Jyväskylä, Jyväskylä, Finland
| | - N Smirnov
- Yale University, New Haven, Connecticut, United States
| | - R J M Snellings
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | | | - J Song
- Department of Physics, Pusan National University, Pusan, Republic of Korea
| | - M Song
- Yonsei University, Seoul, Republic of Korea
| | - F Soramel
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Padova, Italy
| | - S Sorensen
- University of Tennessee, Knoxville, Tennessee, United States
| | - F Sozzi
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - E Spiriti
- INFN, Laboratori Nazionali di Frascati, Frascati, Italy
| | - I Sputowska
- The Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - B K Srivastava
- Purdue University, West Lafayette, Indiana, United States
| | - J Stachel
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - I Stan
- Institute of Space Science (ISS), Bucharest, Romania
| | - P Stankus
- Oak Ridge National Laboratory, Oak Ridge, Tennessee, United States
| | - E Stenlund
- Division of Experimental High Energy Physics, University of Lund, Lund, Sweden
| | - D Stocco
- SUBATECH, IMT Atlantique, Université de Nantes, CNRS-IN2P3, Nantes, France
| | - M M Storetvedt
- Faculty of Engineering, Bergen University College, Bergen, Norway
| | - P Strmen
- Faculty of Mathematics, Physics and Informatics, Comenius University, Bratislava, Slovakia
| | - A A P Suaide
- Universidade de São Paulo (USP), São Paulo, Brazil
| | | | - C Suire
- Institut de Physique Nucléaire d'Orsay (IPNO), Université Paris-Sud, CNRS-IN2P3, Orsay, France
| | - M Suleymanov
- COMSATS Institute of Information Technology (CIIT), Islamabad, Pakistan
| | - M Suljic
- Dipartimento di Fisica dell'Università and Sezione INFN, Trieste, Italy
| | - R Sultanov
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - M Šumbera
- Nuclear Physics Institute, Academy of Sciences of the Czech Republic, Řež u Prahy, Czech Republic
| | - S Sumowidagdo
- Indonesian Institute of Sciences, Jakarta, Indonesia
| | - K Suzuki
- Stefan Meyer Institut für Subatomare Physik (SMI), Vienna, Austria
| | - S Swain
- Institute of Physics, Bhubaneswar, India
| | - A Szabo
- Faculty of Mathematics, Physics and Informatics, Comenius University, Bratislava, Slovakia
| | - I Szarka
- Faculty of Mathematics, Physics and Informatics, Comenius University, Bratislava, Slovakia
| | - U Tabassam
- COMSATS Institute of Information Technology (CIIT), Islamabad, Pakistan
| | - J Takahashi
- Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
| | - G J Tambave
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - N Tanaka
- University of Tsukuba, Tsukuba, Japan
| | - M Tarhini
- Institut de Physique Nucléaire d'Orsay (IPNO), Université Paris-Sud, CNRS-IN2P3, Orsay, France
| | - M Tariq
- Department of Physics, Aligarh Muslim University, Aligarh, India
| | - M G Tarzila
- National Institute for Physics and Nuclear Engineering, Bucharest, Romania
| | - A Tauro
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - G Tejeda Muñoz
- Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - A Telesca
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - C Terrevoli
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Padova, Italy
| | - B Teyssier
- Université de Lyon, Université Lyon 1, CNRS/IN2P3, IPN-Lyon, Villeurbanne, Lyon, France
| | - D Thakur
- Indian Institute of Technology Indore, Indore, India
| | - S Thakur
- Variable Energy Cyclotron Centre, Kolkata, India
| | - D Thomas
- The University of Texas at Austin, Physics Department, Austin, Texas, United States
| | - F Thoresen
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - R Tieulent
- Université de Lyon, Université Lyon 1, CNRS/IN2P3, IPN-Lyon, Villeurbanne, Lyon, France
| | - A Tikhonov
- Institute for Nuclear Research, Academy of Sciences, Moscow, Russia
| | - A R Timmins
- University of Houston, Houston, Texas, United States
| | - A Toia
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - S Tripathy
- Indian Institute of Technology Indore, Indore, India
| | - S Trogolo
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | - G Trombetta
- Dipartimento Interateneo di Fisica 'M. Merlin' and Sezione INFN, Bari, Italy
| | - L Tropp
- Faculty of Science, P.J. Šafárik University, Košice, Slovakia
| | - V Trubnikov
- Bogolyubov Institute for Theoretical Physics, Kiev, Ukraine
| | | | - B A Trzeciak
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - T Tsuji
- University of Tokyo, Tokyo, Japan
| | - A Tumkin
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | - R Turrisi
- INFN, Sezione di Padova, Padova, Italy
| | - T S Tveter
- Department of Physics, University of Oslo, Oslo, Norway
| | - K Ullaland
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - E N Umaka
- University of Houston, Houston, Texas, United States
| | - A Uras
- Université de Lyon, Université Lyon 1, CNRS/IN2P3, IPN-Lyon, Villeurbanne, Lyon, France
| | - G L Usai
- Dipartimento di Fisica dell'Università and Sezione INFN, Cagliari, Italy
| | - A Utrobicic
- Physics department, Faculty of science, University of Zagreb, Zagreb, Croatia
| | - M Vala
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
- Technical University of Košice, Košice, Slovakia
| | - J Van Der Maarel
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - J W Van Hoorne
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M van Leeuwen
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - T Vanat
- Nuclear Physics Institute, Academy of Sciences of the Czech Republic, Řež u Prahy, Czech Republic
| | - P Vande Vyvre
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D Varga
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - A Vargas
- Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - M Vargyas
- University of Jyväskylä, Jyväskylä, Finland
| | - R Varma
- Indian Institute of Technology Bombay (IIT), Mumbai, India
| | - M Vasileiou
- National and Kapodistrian University of Athens, Physics Department, Athens, Greece
| | - A Vasiliev
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - A Vauthier
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
| | - O Vázquez Doce
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - V Vechernin
- V. Fock Institute for Physics, St. Petersburg State University, St. Petersburg, Russia
| | - A M Veen
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - A Velure
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - E Vercellin
- Dipartimento di Fisica dell'Università and Sezione INFN, Turin, Italy
| | | | - R Vernet
- Centre de Calcul de l'IN2P3, Villeurbanne, Lyon, France
| | - R Vértesi
- Wigner Research Centre for Physics, Hungarian Academy of Sciences, Budapest, Hungary
| | - L Vickovic
- Technical University of Split FESB, Split, Croatia
| | - S Vigolo
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | | | - Z Vilakazi
- University of the Witwatersrand, Johannesburg, South Africa
| | - O Villalobos Baillie
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | | | - A Vinogradov
- National Research Centre Kurchatov Institute, Moscow, Russia
| | - L Vinogradov
- V. Fock Institute for Physics, St. Petersburg State University, St. Petersburg, Russia
| | - T Virgili
- Dipartimento di Fisica 'E.R. Caianiello' dell'Università and Gruppo Collegato INFN, Salerno, Italy
| | - V Vislavicius
- Division of Experimental High Energy Physics, University of Lund, Lund, Sweden
| | - A Vodopyanov
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - M A Völkl
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - K Voloshin
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - S A Voloshin
- Wayne State University, Detroit, Michigan, United States
| | - G Volpe
- Dipartimento Interateneo di Fisica 'M. Merlin' and Sezione INFN, Bari, Italy
| | - B von Haller
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - I Vorobyev
- Excellence Cluster Universe, Technische Universität München, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
| | - D Voscek
- Technical University of Košice, Košice, Slovakia
| | - D Vranic
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - J Vrláková
- Faculty of Science, P.J. Šafárik University, Košice, Slovakia
| | - B Wagner
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - H Wang
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - M Wang
- Central China Normal University, Wuhan, China
| | | | - Y Watanabe
- University of Tokyo, Tokyo, Japan
- University of Tsukuba, Tsukuba, Japan
| | - M Weber
- Stefan Meyer Institut für Subatomare Physik (SMI), Vienna, Austria
| | - S G Weber
- Research Division and ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - D F Weiser
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - S C Wenzel
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J P Wessels
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - U Westerhoff
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - A M Whitehead
- Physics Department, University of Cape Town, Cape Town, South Africa
| | - J Wiechula
- Institut für Kernphysik, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany
| | - J Wikne
- Department of Physics, University of Oslo, Oslo, Norway
| | - G Wilk
- National Centre for Nuclear Studies, Warsaw, Poland
| | - J Wilkinson
- INFN, Sezione di Bologna, Bologna, Italy
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - G A Willems
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | | | - E Willsher
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - B Windelband
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - W E Witt
- University of Tennessee, Knoxville, Tennessee, United States
| | - S Yalcin
- KTO Karatay University, Konya, Turkey
| | | | - P Yang
- Central China Normal University, Wuhan, China
| | - S Yano
- Hiroshima University, Hiroshima, Japan
| | - Z Yin
- Central China Normal University, Wuhan, China
| | - H Yokoyama
- Laboratoire de Physique Subatomique et de Cosmologie, Université Grenoble-Alpes, CNRS-IN2P3, Grenoble, France
- University of Tsukuba, Tsukuba, Japan
| | - I-K Yoo
- Department of Physics, Pusan National University, Pusan, Republic of Korea
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J H Yoon
- Inha University, Incheon, Republic of Korea
| | - V Yurchenko
- Bogolyubov Institute for Theoretical Physics, Kiev, Ukraine
| | - V Zaccolo
- INFN, Sezione di Torino, Turin, Italy
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - A Zaman
- COMSATS Institute of Information Technology (CIIT), Islamabad, Pakistan
| | - C Zampolli
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - H J C Zanoli
- Universidade de São Paulo (USP), São Paulo, Brazil
| | - N Zardoshti
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - A Zarochentsev
- V. Fock Institute for Physics, St. Petersburg State University, St. Petersburg, Russia
| | - P Závada
- Institute of Physics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - N Zaviyalov
- Russian Federal Nuclear Center (VNIIEF), Sarov, Russia
| | | | - M Zhalov
- Petersburg Nuclear Physics Institute, Gatchina, Russia
| | - H Zhang
- Central China Normal University, Wuhan, China
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - X Zhang
- Central China Normal University, Wuhan, China
| | - Y Zhang
- Central China Normal University, Wuhan, China
| | - C Zhang
- Institute for Subatomic Physics of Utrecht University, Utrecht, Netherlands
| | - Z Zhang
- Central China Normal University, Wuhan, China
- Laboratoire de Physique Corpusculaire (LPC), Clermont Université, Université Blaise Pascal, CNRS-IN2P3, Clermont-Ferrand, France
| | - C Zhao
- Department of Physics, University of Oslo, Oslo, Norway
| | - N Zhigareva
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - D Zhou
- Central China Normal University, Wuhan, China
| | - Y Zhou
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | - Z Zhou
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - H Zhu
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - J Zhu
- Central China Normal University, Wuhan, China
| | - X Zhu
- Central China Normal University, Wuhan, China
| | - A Zichichi
- Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi', Rome, Italy
- Dipartimento di Fisica e Astronomia dell'Università and Sezione INFN, Bologna, Italy
| | - A Zimmermann
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - M B Zimmermann
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - G Zinovjev
- Bogolyubov Institute for Theoretical Physics, Kiev, Ukraine
| | - J Zmeskal
- Stefan Meyer Institut für Subatomare Physik (SMI), Vienna, Austria
| | - S Zou
- Central China Normal University, Wuhan, China
| |
Collapse
|
219
|
Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A. Somatostatinrezeptor-PET/CT. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1636560] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
ZusammenfassungDie vorliegende Handlungsempfehlung dient als Grundlage zur Qualitätssicherung der Somatostatinrezeptor (SSTR-) PET/CT bei onkologischen Patienten. Die Leitlinie wurde interdisziplinär erarbeitet und enthält neben der Definition und Zielsetzung einen Konsens hinsichtlich der erforderlichen klinischen Hintergrundinformationen, Indikationsstellung, Durchführung, Auswertung, Dokumentation und Befunderstellung. Dabei werden die beiden gebräuchlichsten Radiotracer der SSTRPET/ CT (68Ga-DOTATOC und 68Ga-DOTATATE) vertieft dargestellt. Die SSTR-PET/CT erfordert eine enge Interaktion zwischen den zuweisenden und ausführenden Fachdisziplinen unter Berücksichtigung bereits vorhandener Leitlinien und Handlungsempfehlungen europäischer und deutscher Fachgesellschaften, namentlich der European Association of Nuclear Medicine (EANM), der Deutschen Gesellschaft für Endokrinologie (DGE), Deutschen Gesellschaft für Nuklearmedizin (DGN) und Deutschen Röntgengesellschaft (DRG).
Collapse
|
220
|
Abstract
SummaryImage analysis with the aid of the computer has rapidly developed over the last few years. There are many possibilities of making use of this development in the medical and biological field. This paper is meant to give a rather general overview of recent systematics regarding the existing methodology in image analysis. Furthermore, some parts of these systematics are illustrated in greater detail by recent research work in the German Cancer Research Center. In particular, two applications are reported where special emphasis is laid on mathematical morphology. This relatively new approach to image analysis finds growing interest in the image processing community and has its strength in bridging the gap between a priori knowledge and image analysis procedures.
Collapse
|
221
|
Schmidt M, Decker T, Fehm T, Fuxius S, Harbeck N, Juhasz-Böss I, Thomssen C, Seehase M, Schollenberger L, Ruckes C, Möbus V. Abstract OT2-05-02: A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot2-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Chemotherapy (CTx) is a cornerstone in HR+/HER2- advanced/metastatic breast cancer (a/mBC) after failure of endocrine treatment. In this indication, vinorelbine (VRL) is a well-established cytotoxic drug. There is a high medical need for new options that prolong the time between endocrine failure and intensive CTx, which is commonly associated with impaired quality of life and serious side effects. Metronomic CTx was shown to induce disease control in a/mBC with a favorable safety profile. This innovative approach involving continuous daily dosing of oral VRL, which could provide anti-angiogenic and immune-modulatory properties, has not been investigated so far in this indication.
Trial Design
VinoMetro is an open-label, single-arm, phase II study (Simon two-stage minimax) of metronomic daily oral VRL (30 mg/day) as first-line CTx. The study involves strict safety monitoring with an initial safety run-in. It is accompanied by a steering committee and supervised by an independent data safety and monitoring board (DSMB). The main objectives are to estimate efficacy in terms of clinical benefit rate after 24 weeks of treatment (primary endpoint) and the progression-free survival, amongst others, as well as the assessment of safety and quality of life. Patients with HR+/HER2- a/mBC having failed or being no candidate for endocrine therapy (targeted combinations allowed) and being naïve to palliative CTx are eligible, if they exhibit ECOG 0-1. The main exclusion criteria are prior vinca-alkaloids, aggressive disease requiring combination CTx and CNS involvement.
Until 2017-05-31, 7 patients were enrolled. It is planned to include 45 (39 evaluable) patients at 8 German sites until 09/2018. Scheduled completion date is 09/2019. Two interim analyses are planned (first analysis: safety evaluation based on the 10 initial patients with predefined stopping rules). Depending on recruitment, it is planned to include the interim safety data in the congress presentation.
VinoMetro is an investigator initiated trial (NCT03007992) sponsored by the University Medical Centre of Johannes Gutenberg-University Mainz, Germany, and supported by an unrestricted grant provided by Pierre Fabre Pharma GmbH (Freiburg, Germany).
Citation Format: Schmidt M, Decker T, Fehm T, Fuxius S, Harbeck N, Juhasz-Böss I, Thomssen C, Seehase M, Schollenberger L, Ruckes C, Möbus V. A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-05-02.
Collapse
Affiliation(s)
- M Schmidt
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - T Decker
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - T Fehm
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - S Fuxius
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - N Harbeck
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - I Juhasz-Böss
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - C Thomssen
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - M Seehase
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - L Schollenberger
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - C Ruckes
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| | - V Möbus
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz, Mainz, Germany; Schwerpunktpraxis für Hämatologie und Onkologie, Ravensburg, Germany; Frauenklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Onkologische Schwerpunktpraxis, Heidelberg, Germany; Brustzentrum, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany; Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle, Halle (Saale), Germany; Interdisziplinäres Zentrum Klinische Studien (IZKS), Universitätsmedizin Mainz, Mainz, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
| |
Collapse
|
222
|
Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Hardy-Bessard AC, Senkus-Konefka E, Cognetti F, Palmieri C, Gelmon K, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Although endocrine therapy (ET) is recommended as first-line therapy for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) up to 50% of patients receive chemotherapy in this setting. Meanwhile new targeted treatment options for combination with ET have been developed and endocrine-based therapy with the CDK4/6 inhibitor Palbociclib (P) improves the progression free survival (PFS) of ET alone by about 50%. So far, there is no data comparing chemotherapy with or without maintenance ET and ET in combination with P as first-line therapy. Patients included in clinical trials are often criticized not to mirror the general breast cancer population and every-day clinical practice due to rigid inclusion and exclusion criteria, limited number of treatment options, strict monitoring intervals and study assessments.
Methods:
PADMA trial is a so called low intervention trial with no rigid inclusion and exclusion criteria, and study assessments.Patients with first-line HR+/HER2- MBC who are candidate for mono-chemotherapy will be eligible to receive either P plus ET per label or mono-chemotherapy per investigator´s choice with or without maintenance ET (1:1 randomization). Primary objective is to compare the time-to-treatment failure (TTF) for patients randomized to receive the mono-chemotherapy treatment strategy versus those randomized to receive P and ET. TTF is defined as time from randomization to discontinuation of treatment due to disease progression, treatment toxicity, patient's preference, or death. Main secondary objectives are progression free survival, overall survival at 36 months, amongst other time to event endpoints as well as toxicity and compliance. All patients receive a specific mobile device (PADMA-Phone) and a validated wearable device (ActiWatch) in order to collect data regarding sleep and activity levels, patient well-being and health care utilization (number and duration of phone calls, and patient visits to investigator site) for assessment of daily monitoring treatment impact (DMTI).
Results:
Overall, 360 patients will be accrued to show an improved TTF for P in combination with ET compared to mono-chemotherapy of investigator´s choice with or without maintenance ET. Recruitment will start in QIII/2017 and is planned for approximately 18 months in 100 sites in Germany, Spain, Poland, Italy, France, UK and Canada.
Conclusions:
The aim of PADMA is to demonstrate that an endocrine-based strategy consisting of ET plus P is superior to a chemotherapy-based strategy as first-line therapy in women with HR+/HER2- MBC in a real world setting. Assessment of patient-reported outcome, health care utilization, and sleep and activity levels will deliver important information on the differences between endocrine-based and chemotherapy-based treatment.
Citation Format: Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Hardy-Bessard A-C, Senkus-Konefka E, Cognetti F, Palmieri C, Gelmon K, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-04.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - J Barinoff
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - S Seiler
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - T Decker
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Denkert
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - A-C Hardy-Bessard
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - E Senkus-Konefka
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - F Cognetti
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Palmieri
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - K Gelmon
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - K Luebbe
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - J Furlanetto
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - V Mueller
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Mundhenke
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Schmidt
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - G von Minckwitz
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Uhlig
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - N Burchardi
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Thill
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| |
Collapse
|
223
|
Feiten S, Scholl I, Schmidt M, Dünnebacke J, Franzen A, Ernst W, Weide R. Abstract P4-11-07: Shared decision making (SDM) in routine care treatment of breast cancer patients – a survey of patients following surgery. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The aim of shared decision making (SDM), defined as an interaction between patient and attending physician(s), is a treatment decision in which patients are meaningfully involved. Based on mutual agreement and active participation the awareness of a choice should be created and the choice respected. Many preference-sensitive decisions have to be made in breast cancer treatment. However, little is known about the implementation of SDM in German breast cancer care. We therefore investigated the process of SDM from the patients' perspective.
Methods: All breast cancer patients who underwent surgery in one of four certified breast cancer centers in Germany between 07/2016 and 12/2016 were invited by mail to participate in the survey. The experienced decision-making process was assessed using the 9-item Shared Decision Making Questionnaire (SDM-Q-9). SDM-Q-9 items were rated on a 6-point scale ranging from "completely disagree" to "completely agree", added together and transformed into a scale ranging from 0 to 100. The higher the total score the higher the experienced degree of participation in the decision-making process. The survey also assessed patients' satisfaction with treatment, satisfaction with decisions and decisional control preferences, and included a range of demographic and clinical questions. For most items we asked the participants to separately rate decision-making consultations with their inpatient hospital doctors, outpatient gynecologists, outpatient oncologists and primary care providers (PCP). The project is still ongoing, data of approximately 300 patients will be presented at the meeting in December.
Results: Of 289 patients approached by mail, 143 filled in the survey (response rate: 49%). Median age at the time of the survey was 62 years (36-89). 83% had breast conserving surgery, 17% mastectomy. 74% were treated with radiation, 31% received neo-/adjuvant chemotherapy. 14% were off-treatment at the time of survey participation, 67% still received antihormonal therapy, 9% anti HER2 treatment, 7% chemotherapy and 2% radiation. Inpatient hospital doctors achieved the highest SDM-Q-9 score (mean of 75, standard deviation of 22) indicating the highest degree of SDM. Oncologists, gynecologists and PCP were rated quite comparable with a mean score of 72 each and standard deviations (SD) of 27, 22 and 31. The mean score for all groups of doctors was 73. For items concerning satisfaction with quality and amount of doctors' information and participation in medical decisions patients showed a high degree of satisfaction, resulting in mean values of 3.6 and 3.5 with SD of 0.6 on a 4-point scale ranging from "1" "very unsatisfied" to "4" "very satisfied".
Conclusions: A considerable number of patients took part in the survey. Overall, patients reported to have experienced SDM in many situations where treatment decisions were necessary. Patients were quite satisfied with the quality of information and their participation in medical decisions. However, we do not know whether non-respondents might have had different experiences regarding their treatment decision-making. Further research should include SDM expert observations of breast cancer treatment decisions to validate these findings.
Citation Format: Feiten S, Scholl I, Schmidt M, Dünnebacke J, Franzen A, Ernst W, Weide R. Shared decision making (SDM) in routine care treatment of breast cancer patients – a survey of patients following surgery [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-11-07.
Collapse
Affiliation(s)
- S Feiten
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - I Scholl
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - M Schmidt
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - J Dünnebacke
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - A Franzen
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - W Ernst
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - R Weide
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| |
Collapse
|
224
|
Möbus V, Mahlberg R, Janni W, Tomé O, Marmé F, Forstbauer H, Reimer T, von der Assen A, Reinisch M, Lorenz R, Schmatloch S, Schmidt M, Sinn B, Klutinus N, Stickeler E, Untch M, Seiler S, Burchardi N, von Minckwitz G, Loibl S. Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-20-09] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
A new subcutaneous (s.c.) formulation of trastuzumab became available in 2013 based on equivalent efficacy, pharmacokinetic (PK) profile and safety with the standard intravenous (i.v.) administration, where the s.c. trastuzumab was administered only into the thigh. As an s.c. injection into the abdominal wall (abdw) might be more convenient for patients (pts) and health care professionals, the PK profile of s.c. trastuzumab injected into the thigh vs the abdw in pts with HER2+ early BC needs to be evaluated.
Methods
GAIN-2 study compared two intense dose-dense (idd) anthracycline/taxane containing regimens. After completion of the anthracycline and i.v. trastuzumab given concurrently with taxanes, HER2+ BC pts were randomized in a 1:1 ratio to continue adjuvant s.c. trastuzumab 600mg fixed dose injected every 3 weeks either into the thigh or the abdw. Randomization was stratified according to CT arm [(iddEnPC) vs tailored dd CT (dtEC-dtD)] and age (≤50 vs >50). Pts in the EnPC arm received 14 and in the dtEC-dtD arm 15 cycles of s.c. trastuzumab.
For the PK profile of s.c. trastuzumab serum samples collected before cycle 7, on days 2, 4, 8, 15 and 21 of cycle 7 are evaluated. With a total sample size of 30 (15 per group), the simulated 90% two-sided CI for the area under the plasma concentration (AUC0-last) will be (0.79-1.27) and for the peak drug concentration (Cmax) will be (0.77-1.30). Allowing for a dropout rate of 15%, 18 pts per group will be included in the PK analysis.
The primary objective was to assess the PK profile of s.c. trastuzumab injected into the thigh vs the abdw. The secondary objectives included safety and tolerability.
Results
The per-protocol (pp) set consists of 30 pts (17 in the thigh group and 13 in the abdw group). Baseline characteristics were well balanced between the groups. The log-transformed Geometric Least Square Means (GLSM) for Cmax were 11.77 and 11.52 in the thigh and the abdw group, respectively. The geo-mean ratio (on the original scale) for Cmax was 1.29 (90% CI 1.05-1.58). The log-transformed GLSM for AUC0-last were 14.54 and 14.28 in the thigh and the abdw group, respectively. The geo-mean ratio for AUC0-last was 1.29 (90% CI 1.02-1.63).
Overall 29 pts (96.7%) reported any grade and 5 pts (16.7%) high grade adverse events (AEs). The incidence of any grade AEs was similar between the two groups. The most common AEs were anemia (70.6% for the thigh vs 61.5% for the abdw group, p=0.705), leukopenia (80.0% for both groups, p=1.000) and fatigue (47.1% for the thigh vs 76.9% for the abdw group, p=0.141). 6 serious AEs were reported (2 in the thigh vs 4 in the abdw group). The final PK results of s.c. trastuzumab will be presented at the meeting.
Conclusions
Bioavailability of s.c. trastuzumab as reflected by peak and total exposure measured in cycle 7 was approx. 30% higher if administered into the thigh than into the abdw in pts with HER2+ primary BC treated after dose-dense CT plus i.v. trastuzumab. However, no increased toxicity was observed. Study limitations were that no cross-over design was used and number of pts satisfying criteria for pp-set were different in the arms.
Citation Format: Möbus V, Mahlberg R, Janni W, Tomé O, Marmé F, Forstbauer H, Reimer T, von der Assen A, Reinisch M, Lorenz R, Schmatloch S, Schmidt M, Sinn B, Klutinus N, Stickeler E, Untch M, Seiler S, Burchardi N, von Minckwitz G, Loibl S. Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-20-09.
Collapse
Affiliation(s)
- V Möbus
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - R Mahlberg
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - W Janni
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - O Tomé
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - F Marmé
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - H Forstbauer
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - T Reimer
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - A von der Assen
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - M Reinisch
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - R Lorenz
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - S Schmatloch
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - M Schmidt
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - B Sinn
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - N Klutinus
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - E Stickeler
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - M Untch
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - S Seiler
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - N Burchardi
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - G von Minckwitz
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| | - S Loibl
- Klinikum Frankfurt; Klinikum Mutterhaus Mitte, Trier; Universitätsklinikum Ulm; St. Vincentius-Kliniken gAG, Karlsruhe; Universitätsklinikum Heidelberg; GOSPL - Gesellschaft für Onkologische Studien, Troisdorf; Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt Rostock; Franziskus-Hospital Harderberg; Kliniken Essen-Mitte; Frauenärztl. Gemeinschafts- u. Schwerpunktpraxis Onkologie, Braunschweig; Elisabeth Krankenhaus Kassel; Universitätsmedizin Mainz; Charité - Universitätsmedizin Berlin; HELIOS Klinikum Pforzheim GmbH Brustzentrum; Universitätsklinikum Freiburg; HELIOS Klinikum Berlin Buch; German Breast Group
| |
Collapse
|
225
|
Campone M, Sachdev J, Bianchi GV, Beck JT, Martínez-Jáñez N, Cortes J, Schmidt M, Zamagni C, Chen P, Miller J, Fandi A, Gianni L. Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-10-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Most patients diagnosed with breast cancer have ER+ tumors. Treatment of ER+ MBC typically involves endocrine therapy, including aromatase inhibitors and selective ER modulators such as tamoxifen; however, many patients develop resistance. Fulvestrant, an ER antagonist, is a commonly prescribed second- or third-line therapy for postmenopausal patients who have progressed on endocrine therapy; although, most patients will eventually develop resistance to this drug as well. It was hypothesized that CC-486, an oral formulation of azacitidine, may resensitize patients to endocrine therapy and possibly delay resistance to fulvestrant through the epigenetic regulation of certain genes.
Methods: 97 postmenopausal female patients aged ≥ 18 years with ER+, HER2− MBC refractory to an aromatase inhibitor were randomized 1:1 to receive CC-486 300 mg on days 1 through 21 and fulvestrant 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent 28-day cycles or the same fulvestrant regimen alone. The primary endpoint was progression-free survival (PFS) based on investigator's assessment using RECIST version 1.1 and summarized by the Kaplan-Meier method. A Cox proportional hazards model was used to estimate the hazard ratio (HR; including a 2-sided 95% CI), and a log-rank test was used to calculate P values for comparisons between treatment arms. Key secondary endpoints included objective response rate (ORR), overall survival (OS), and safety.
Results: 48 patients were included in the CC-486 + fulvestrant arm and 49 in the fulvestrant-alone arm. Median age was 63 years. Baseline characteristics were generally balanced between treatment groups, with some exceptions. The CC-486 + fulvestrant treatment cohort had fewer patients aged ≥ 65 years (40% vs 49%), with an ECOG PS of 1 (25% vs 57%), or with liver metastases (29% vs 43%) than did the fulvestrant-alone cohort. At the time of this analysis, 36 patients (75%) in the CC-486 + fulvestrant arm and 40 patients (82%) in the fulvestrant-alone arm had discontinued treatment, mostly due to progressive disease (81% and 90%, respectively). Median PFS was 5.5 months in both treatment groups (HR 0.87; 95% CI, 0.54 - 1.42; P = 0.599). ORR was 8.3% vs 2.0% in patients receiving CC-486 + fulvestrant vs fulvestrant alone, respectively. Median OS has not been reached. In patients who received CC-486 + fulvestrant, the most common any-grade nonhematologic treatment-emergent adverse events (TEAEs) were nausea (78%), vomiting (78%), diarrhea (44%), and constipation (41%), and the most frequent any-grade hematologic TEAE was neutropenia (26%). Of patients who discontinued due to AEs, most patients receiving CC-486 + fulvestrant treatment discontinued due to gastrointestinal (GI) TEAEs.
Conclusion: The addition of CC-486 to fulvestrant did not improve PFS in patients with ER+, HER2− MBC compared with fulvestrant alone, and GI TEAEs were reported in a majority of patients. These results do not support further evaluation of this combination in this setting.
Citation Format: Campone M, Sachdev J, Bianchi GV, Beck JT, Martínez-Jáñez N, Cortes J, Schmidt M, Zamagni C, Chen P, Miller J, Fandi A, Gianni L. Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-10-07.
Collapse
Affiliation(s)
- M Campone
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - J Sachdev
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - GV Bianchi
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - JT Beck
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - N Martínez-Jáñez
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - J Cortes
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - M Schmidt
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - C Zamagni
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - P Chen
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - J Miller
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - A Fandi
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| | - L Gianni
- Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain Cedex, France; HonorHealth Research Institute/ TGEN, Scottsdale, AZ; Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; Highlands Oncology Group, Fayetteville, AR; Hospital Universitario Ramon y Cajal, Madrid, Spain; Vall d'Hebron Institute of Oncology, Madrid, Spain; University Medical Center Mainz, Mainz, Germany; Policlinico Saint'Orsola-Malpighi, Bologna, Italy; Celgene Corporation, Summit, NJ; Ospedale San Raffaele, Milano, Italy
| |
Collapse
|
226
|
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Schmidt M, Klare P, Rezai M, Rautenberg B, Klutinus N, Rhein U, Mousa K, Ricardo-Vitorino S, von Minckwitz G, Bliss J. Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs3-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Inhibition of COX-2 has been shown to attenuate the metastatic process in pre-clinical models of human breast cancer (BC). The primary aim of this study was to assess the effect of 2 years adjuvant therapy with the COX-2 inhibitor celecoxib compared with placebo in HER2-ve primary BC patients.
Patients & Methods
Patients were randomised in a 2:1 ratio to receive celecoxib 400mg once daily or placebo for 2 years. Patients had to have completely resected BC with prior local and systemic adjuvant treatment according to local practice. Concurrent radiotherapy was permitted and hormone receptor +ve patients received endocrine therapy according to local practice. Patients with HER2+ or node negative, T1 and grade 1 disease were excluded. Median age of patients was 55 years (IQR: 49-63). 50% of patients had tumours >2cm; 42% were grade 3; 48% had node +ve disease. According to local assessment 73% were ER/PgR +ve. Primary endpoint was Disease Free Survival (DFS); defined as time from randomisation to date of first event, with events contributing to analysis defined as recurrence (distant/local), new primary BC (ipsilateral/contralateral) and death. Secondary endpoints included Overall Survival (OS), toxicity, cardiovascular mortality and incidence of second primaries. Subgroup analysis by hormone receptor status was pre-planned. Survival endpoints are analysed using Cox-proportional hazards and log-rank tests; restricted mean survival is used where proportional hazards do not hold.
Results
Between January 2007 and November 2012, 2639 patients were randomised (1763 celecoxib; 876 placebo) from 181 centres across the UK and Germany. At 13th April 2017, median follow up was 60 months (IQR: 48-72) with 428 DFS events reported. Unadjusted survival analysis results are presented below, with hazard ratio<1 favouring celecoxib:
5 year survival estimate (95% CI)Hazard ratio (95% CI)p-valueDFS (all patients) Celecoxib83% (81, 85)1.02 (0.83 – 1.24)0.88Placebo83% (80, 86)1- DFS within ER+ Celecoxib87% (85, 89)0.89 (0.69 – 1.16)0.40Placebo86% (83, 89)1- DFS within ER- Celecoxib72% (68, 76)1.17 (0.85 – 1.61)0.33Placebo75% (69, 80)1- OS (all patients) Celecoxib90% (88, 91)0.97 (0.75 – 1.25)0.81Placebo90% (88, 92)1-
The interaction between ER status and treatment was not significant; p=0.36.
In the celecoxib and placebo groups there were 17 and 8 deaths respectively in patients who had not relapsed. These were due to cardiac (n=3; 2) and other (n=14; 6) in the celecoxib and placebo groups respectively; none were GI related. In total 304 serious adverse events were observed in 265 patients (186/1763 celecoxib; 79/876 placebo). In the celecoxib and placebo groups respectively these were related to cardiac (n=12; 7), GI (n=9; 2) and other (n=193; 81). Work is ongoing to determine whether a subset of ER+ patients whose primary tumours show the characteristics of a COX-2 signature receive greater benefit from celecoxib.
Conclusions
There is no benefit of celecoxib in the ITT population. Further exploratory studies focussing on the ER+ subpopulation are ongoing. Celecoxib treatment is not associated with significant toxicity when compared to placebo in this population of BC patients.
Citation Format: Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Schmidt M, Klare P, Rezai M, Rautenberg B, Klutinus N, Rhein U, Mousa K, Ricardo-Vitorino S, von Minckwitz G, Bliss J. A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS3-03.
Collapse
Affiliation(s)
- RC Coombes
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - H Tovey
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - L Kilburn
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - J Mansi
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - C Palmieri
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - J Bartlett
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - J Hicks
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - A Makris
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - A Evans
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - S Loibl
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - C Denkert
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - E Murray
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - R Grieve
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - R Coleman
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - M Schmidt
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - P Klare
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - M Rezai
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - B Rautenberg
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - N Klutinus
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - U Rhein
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - K Mousa
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - S Ricardo-Vitorino
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - G von Minckwitz
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - J Bliss
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| |
Collapse
|
227
|
Thaler S, Schad A, Kirkpatrick CJ, Sleeman JP, Springer E, Schmidt M, Cotarelo CL. Abstract P5-10-01: Cellular senescence within HER2-amplified breast cancer: Potential implications for breast cancer immune surveillance and HER2-targeted therapy resistance. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-10-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Oncogene-induced senescence is considered as a barrier to tumor progression that arrests cells at risk for malignant transformation. Nevertheless, numerous findings demonstrate that senescent cells may also have the opposite function and promote tumor progression through the release of multiple factors called the senescence-associated secretory phenotype or senescence secretome. It is likely that the composition and the physiological consequences mediated by the senescence secretome are dependent on the oncogenes that trigger the senescence program. Breast cancer represents a heterogenous disease that can be divided into breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities. Therefore, tumor initiation and progression of breast cancer subtypes is triggered by variable oncogenic stimuli, and differences in the senescence secretomes within breast tumors might be responsible for tumor initiation, progression, metastasis and therapeutic response. Beside many studies concerning the role of senescence as a barrier to tumor progression using murine xenograft models very few investigations have been performed to elucidate how often senescent tumor cells appear within untreated human tumors, and if present whether these senescent tumor cells may play a role in disease progression, cancer immunosurveillance and therapy resistance.
Methode: In the present study we analysed the appearance of senescent cells within invasive human breast cancers from 129 untreated patients. Cellular senescence was detected by the use of SAβ-gal staining and by immunohistochemical detection of p16, p21, p53, Ki67 and lamin B1.
Results: Detection of cellular senescence by the use of SAβ-gal staining and detection of p16, p53, Ki67 and lamin B1 within invasive breast carcinomas indicate that senescent tumor cells varies strongly according to the breast cancer subtype. The highest percentages of senescent tumor cells exist within in the HER2-positive and luminal A breast carcinomas whereas no or very few senescent tumor cells were found in triple negative breast tumors. Based on these findings we suggest that the composition of secretomes released by senescent tumor cells from different breast cancer subtypes might be very distinct in respect to their ability to recruit immune cells, which can eliminate senescent tumor cells on one hand and regulate tumor growth, immune surveillance and therapy resistance on the other.
Conclusion: Further characterization of senescent secretomes from HER2 and other breast cancer subtypes and their potential role in tumor progression, immune surveillance and therapy response might be warranted for the understanding of cancer biology as well as prognostic and therapeutic applications.
Citation Format: Thaler S, Schad A, Kirkpatrick CJ, Sleeman JP, Springer E, Schmidt M, Cotarelo CL. Cellular senescence within HER2-amplified breast cancer: Potential implications for breast cancer immune surveillance and HER2-targeted therapy resistance [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-10-01.
Collapse
Affiliation(s)
- S Thaler
- Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Institute of Pathology, University Medical Center, Johannes Gutenberg University, Mainz, Germany; KIT Campus Nord, Institute for Toxicology and Genetics, Karlsruhe, Germany; University Medical Center, Johannes Gutenberg University, Mainz, Germany
| | - A Schad
- Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Institute of Pathology, University Medical Center, Johannes Gutenberg University, Mainz, Germany; KIT Campus Nord, Institute for Toxicology and Genetics, Karlsruhe, Germany; University Medical Center, Johannes Gutenberg University, Mainz, Germany
| | - CJ Kirkpatrick
- Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Institute of Pathology, University Medical Center, Johannes Gutenberg University, Mainz, Germany; KIT Campus Nord, Institute for Toxicology and Genetics, Karlsruhe, Germany; University Medical Center, Johannes Gutenberg University, Mainz, Germany
| | - JP Sleeman
- Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Institute of Pathology, University Medical Center, Johannes Gutenberg University, Mainz, Germany; KIT Campus Nord, Institute for Toxicology and Genetics, Karlsruhe, Germany; University Medical Center, Johannes Gutenberg University, Mainz, Germany
| | - E Springer
- Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Institute of Pathology, University Medical Center, Johannes Gutenberg University, Mainz, Germany; KIT Campus Nord, Institute for Toxicology and Genetics, Karlsruhe, Germany; University Medical Center, Johannes Gutenberg University, Mainz, Germany
| | - M Schmidt
- Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Institute of Pathology, University Medical Center, Johannes Gutenberg University, Mainz, Germany; KIT Campus Nord, Institute for Toxicology and Genetics, Karlsruhe, Germany; University Medical Center, Johannes Gutenberg University, Mainz, Germany
| | - CL Cotarelo
- Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Institute of Pathology, University Medical Center, Johannes Gutenberg University, Mainz, Germany; KIT Campus Nord, Institute for Toxicology and Genetics, Karlsruhe, Germany; University Medical Center, Johannes Gutenberg University, Mainz, Germany
| |
Collapse
|
228
|
van Vulpen JK, Sweegers MG, Kalter J, Peeters PH, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Steindorf K, Stuiver MM, Hayes S, Mesters I, Knoop H, Goedendorp M, Mutrie N, Thorsen L, Schmidt M, Sonke GS, Bohus M, James EL, Oldenburg HS, Velthuis MJ, Nollet F, Wenzel J, Wiskemann J, Galvão DA, Chinapaw MJ, Irwin ML, Griffith KA, van Weert E, Daley AJ, McConnachie A, Schulz KH, Short CE, Plotnikoff RC, Potthoff K, van Beurden M, van Harten WH, Schmitz KH, Winters-Stone KM, Taaffe DR, van Mechelen W, Kersten MJ, Verdonck-de Leeuw IM, Brug J, Buffart LM, May AM. Abstract P6-12-06: Effect and moderators of exercise on fatigue in patients with breast cancer: Meta-analysis of individual patient data. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-12-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background - Fatigue is one of the most common and disabling complaints in patients with breast cancer and can effectively be reduced by physical exercise, with small to moderate effect sizes. To identify heterogeneity in responses to exercise and to further personalize exercise prescriptions, moderators of exercise effects on fatigue should be investigated. However, most randomized controlled trials (RCTs) are not adequately powered for such analyses. Therefore we conducted meta-analyses using the individual patient data of several exercise RCTs. The aim is to investigate the effect and moderators of physical exercise on cancer-related fatigue in patients with breast cancer.
Methods - Within the Predicting OptimaL cAncer RehabIlitation and Supportive care (POLARIS) consortium, principal investigators of 34 exercise RCTs worldwide have shared their individual patient data. Twenty-two of these RCTs included patients with breast cancer with a total sample size of 3,061. Different questionnaires to assess level of fatigue were used, which was acknowledged by using z-scores in the analysis. A one-step individual patient data meta-analysis, using a linear mixed-effect model adjusted for baseline fatigue, with a random intercept on study (to account for study clustering) was undertaken to investigate effect of exercise on fatigue. The result, a between-group difference in z-scores, corresponds to a Cohen's d effect size. An interaction term was included in the model to assess potential moderators including demographic (age, marital status, education), clinical (body mass index, presence of distant metastasis), intervention-related (intervention timing, delivery mode and duration), and exercise-related (exercise type, frequency, intensity, duration) characteristics.
Results – Exercise significantly reduced fatigue reported by women with breast cancer (β= -0.15, 95% CI -0.21;-0.09). This effect did not differ significantly between patients with different demographic and clinical characteristics (p-valuesinteraction >0.05). Also, neither timing (during or post-treatment) and duration of the intervention, nor exercise-related factors moderated intervention effects on fatigue. Supervised exercise had significantly larger effects on fatigue than unsupervised exercise (βdifference= -0.17, 95%CI -0.28;-0.05). Compared to the control group, supervised exercise significantly improved fatigue (β = -0.21, 95%CI = -0.28;-0.14), while unsupervised exercise did not (β = -0.04, 95%CI = -0.14;0.06).
Conclusion – Exercise significantly reduces fatigue in patients with breast cancer across subgroups formed on the basis of age, marital status, education level, body mass index, and presence of distant metastasis. The effect of exercise is significantly larger when performed under supervision. Hence, exercise, and preferably supervised exercise, represents a viable intervention for the prevention and treatment of fatigue among patients with breast cancer.
Citation Format: van Vulpen JK, Sweegers MG, Kalter J, Peeters PH, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Steindorf K, Stuiver MM, Hayes S, Mesters I, Knoop H, Goedendorp M, Mutrie N, Thorsen L, Schmidt M, Sonke GS, Bohus M, James EL, Oldenburg HS, Velthuis MJ, Nollet F, Wenzel J, Wiskemann J, Galvão DA, Chinapaw MJ, Irwin ML, Griffith KA, van Weert E, Daley AJ, McConnachie A, Schulz K-H, Short CE, Plotnikoff RC, Potthoff K, van Beurden M, van Harten WH, Schmitz KH, Winters-Stone KM, Taaffe DR, van Mechelen W, Kersten M-J, Verdonck-de Leeuw IM, Brug J, Buffart LM, May AM. Effect and moderators of exercise on fatigue in patients with breast cancer: Meta-analysis of individual patient data [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-12-06.
Collapse
Affiliation(s)
- JK van Vulpen
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - MG Sweegers
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - J Kalter
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - PH Peeters
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - KS Courneya
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - RU Newton
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - NK Aaronson
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - PB Jacobsen
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - K Steindorf
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - MM Stuiver
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - S Hayes
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - I Mesters
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - H Knoop
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - M Goedendorp
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - N Mutrie
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - L Thorsen
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - M Schmidt
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - GS Sonke
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - M Bohus
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - EL James
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - HS Oldenburg
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - MJ Velthuis
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - F Nollet
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - J Wenzel
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - J Wiskemann
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - DA Galvão
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - MJ Chinapaw
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - ML Irwin
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - KA Griffith
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - E van Weert
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - AJ Daley
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - A McConnachie
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - K-H Schulz
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - CE Short
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - RC Plotnikoff
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - K Potthoff
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - M van Beurden
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - WH van Harten
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - KH Schmitz
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - KM Winters-Stone
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - DR Taaffe
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - W van Mechelen
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - M-J Kersten
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - IM Verdonck-de Leeuw
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - J Brug
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - LM Buffart
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| | - AM May
- University Medical Center Utrecht, Utrecht, Netherlands; VU University Medical Center, Amsterdam, Netherlands; University of Alberta, Edmonton, Canada; Edith Cowan University, Joondalup, Australia; Netherlands Cancer Institute, Amsterdam, Netherlands; Moffitt Cancer Center and Research Institute, Tampa; German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT), Heidelberg, Germany; Yale School of Public Health, New Haven; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Australia; University of Maryland, Baltimore; Maastricht University, Maastricht, Netherlands; University of Groningen, Groningen, Netherlands; Academic Medical Center, Amsterdam, Netherlands; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of Glasgow, Glasgow, United Kingdom; Heidelberg University, Mannheim, Germany; Oslo University Hospital, Oslo, Norway; University Medical Center Hamburg-Eppendorf, Ham
| |
Collapse
|
229
|
Urbannek V, Schmidt M, Moka D, Hillger HW, Voth E, Wellner U, Schicha H. Influence of iodine application during radioiodine therapy in case of impending therapy failure. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1632255] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Aim: We investigated whether additional application of “cold” iodine after therapy with radioiodine could result in a prolongation of the effective half life of iodine-131 and would thus lead to an increase of the effective thyroid radiation dose. Methods: Time-activitycurves after therapy with radioiodine were analysed in 25 patients (16 women, 9 men). Nine patients suffered from autonomously functioning thyroid nodules, 5 from autonomous multinodular goiter and 11 from Graves’ disease. These patients had an effective half life shorter than 4 days resulting in an undertreatment of > 20% with respect to the desired effective thyroid radiation dose. 2-4 days after therapy with radioiodine all patients received “cold” iodine for three days in a dose of 3 × 200 μg per day. Results: In 14 of the 25 patients an increase of the effective half life was observed. Patients with an autonomously functioning thyroid nodule showed a mean increase of the effective thyroid radiation dose of 40 ± 44 Gy, patients with toxic multinodular goiter of 29 ± 30 Gy and patients with Graves’ disease of 37 ± 37 Gy. Conclusion: Additional application of “cold” iodine after therapy with radioiodine can prolong the effective half life in selected patients. We suspect a correlation with the thyroid iodine pool. This will be the basis for further investigations hopefully resulting in a better patient preselection to determine who might respond to this therapy.
Collapse
|
230
|
Schmidt M, Scheidhauer K, Urbannek V, Luyken C, Friese M, Voth E, Schicha H. Metastasiertes follikuläres Schilddrüsenkarzinom mit intrakranieller lod-131-Anreicherung in einem Hirnödem bei frontalem Meningeom. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1632241] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
231
|
Schmidt M, Saavedra M, Alegría L, Alvarado N, Fuentes I, Menares P, Kortaberría G, Gargallo L, Saldías C, Leiva A, Radić D. Host-guest interactions of non-steroidal anti-inflammatory drugs on the functionalized dendronized polymeric nanocomposite, Poly(N-tris[((cyano-ethoxy)methyl] methylacrylamide). Journal of Macromolecular Science, Part A 2018. [DOI: 10.1080/10601325.2018.1426389] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- M. Schmidt
- Laboratorio de Química Física de Macromoléculas, Depto Química Física, Facultad de Química, Pontificia Universidad Católica de Chile, Casilla 306, Santiago 22, Chile
| | - M. Saavedra
- Laboratorio de Química Teórica, Facultad de Química y Biología, Universidad de Santiago de Chile (USACH), Casilla 40, Correo 33, Santiago, Chile
| | - L. Alegría
- Centro de Docencia de Ciencias Básicas para Ingeniería, Facultad de Ciencias de la Ingeniería, Universidad Austral de Chile, Casilla 567, Valdivia, Chile
| | - N. Alvarado
- Laboratorio de Química Física de Macromoléculas, Depto Química Física, Facultad de Química, Pontificia Universidad Católica de Chile, Casilla 306, Santiago 22, Chile
| | - I. Fuentes
- Centro de Materiales Poliméricos y Macromoléculas, Instituto de Ciencias Químicas Aplicadas, Facultad de Ingeniería. Centro de Investigación Multidisciplinario de La Araucanía (CIMA), Universidad Autónoma de Chile, Av. Alemania, Temuco, Chile
| | - P. Menares
- Laboratorio de Química Física de Macromoléculas, Depto Química Física, Facultad de Química, Pontificia Universidad Católica de Chile, Casilla 306, Santiago 22, Chile
| | - G. Kortaberría
- Group “Material+Technologies”, Dept Ingeniería Química y M. Ambiente, Escuela Politécnica, Universidad País Vasco/Euskal Herriko Unibersitatea, Donostia, San Sebastián, España
| | - L. Gargallo
- Facultad de Ciencias, Departamento de Química Universidad de Tarapacá, General Velásquez, Arica, Chile
| | - C. Saldías
- Laboratorio de Química Física de Macromoléculas, Depto Química Física, Facultad de Química, Pontificia Universidad Católica de Chile, Casilla 306, Santiago 22, Chile
| | - A. Leiva
- Laboratorio de Química Física de Macromoléculas, Depto Química Física, Facultad de Química, Pontificia Universidad Católica de Chile, Casilla 306, Santiago 22, Chile
| | - D. Radić
- Laboratorio de Química Física de Macromoléculas, Depto Química Física, Facultad de Química, Pontificia Universidad Católica de Chile, Casilla 306, Santiago 22, Chile
| |
Collapse
|
232
|
Vogt H, Bares R, Brenner W, Grünwald F, Kopp J, Reiners C, Schober O, Schümichen C, Schicha H, Sciuk J, Sudbrock F, Wengenmair H, Schmidt M. Verfahrensanweisung für die nuklear medizinische Wächter-Lymphknoten-Diagnostik. Nuklearmedizin 2018; 49:167-72; quiz N19. [DOI: 10.3413/nukmed-321] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2010] [Accepted: 05/07/2010] [Indexed: 11/20/2022]
Abstract
SummaryThe authors present a procedure guideline for scintigraphic detection of sentinel lymph nodes in malignant melanoma and other skin tumours, in breast cancer, in head and neck cancer, and in prostate and penile carcinoma. Important goals of sentinel lymph node scintigraphy comprise reduction of the extent of surgery, lower postoperative morbidity and optimization of histopathological examination focussing on relevant lymph nodes. Sentinel lymph node scintigraphy itself does not diagnose tumorous lymph node involvement and is not indicated when lymph node metastases have been definitely diagnosed before sentinel lymph node scintigraphy. Procedures are compiled with the aim to reliably localise sentinel lymph nodes with a high detection rate typically in early tumour stages. Radiation exposure is low so that pregnancy is not a contraindication for sentinel lymph node scintigraphy. Even with high volumes of scintigraphic sentinel lymph node procedures surgeons, theatre staff and pathologists receive a radiation exposure < 1 mSv/year so that they do not require occupational radiation surveillance.
Collapse
|
233
|
Busemeyer S, Kobe C, Schmidt M, Theissen P, Schicha H, Dietlein M. Recombinant human TSH versus hypo thyroidism. Nuklearmedizin 2018; 49:216-24. [DOI: 10.3413/nukmed-0321-1005] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2010] [Accepted: 09/13/2010] [Indexed: 11/20/2022]
Abstract
SummaryThe primary aim of this study was to compare pharmacoeconomic effects of hypothyroidism secondary to hormone withdrawal (THW) and recombinant human TSH (rhTSH) for followup WBS in patients with differentiated thyroid cancer (DTC). The second aim was to determine patients' preference for one procedure or the other. Patients, methods: This retrospective survey included 327 patients with DTC who underwent at least one in-hospital WBS with rhTSH between 1999 and 2006. They had also undergone THW for WBS. Patients received a two-page questionnaire via mail addressing five symptoms and ten items regarding managing their daily life which was answered by 61.6%. The responder group did not differ from the entire group. The medical and societal cost of both procedures for diagnostic WBS was calculated including direct and all ascertainable indirect cost for the reference year 2005. A sensitivity analysis included the German DRG system of 2007 and 2010. Results: After THW, 94% of patients reported hypothyroid symptoms. Using rhTSH, symptoms occurred significantly less. As a result, 97% of patients favored rhTSH over THW. Mean absence from salaried work was 12.3 days after THW compared to 4 days with rhTSH. Family members of salaried employees missed 3 and 0.7 workdays after THW and rhTSH, respectively. Almost twice as often, medical attention was sought after THW (36%) compared to rhTSH (19 %). Undergoing THW, 48% of patients still used their car while hypothyroid. Our cost calculation revealed a slight benefit of about 89.00 Euro in favour of rhTSH stimulation. Conclusion: Hypothyroidism after THW causes significant morbidity and safety risks. The clinical and societal benefits associated with rhTSH are roughly gained at equivalent overall cost to that of THW.
Collapse
|
234
|
Hellmich M, Lehmacher W, Eschner W, Schmidt M, Kobe C, Schober O, Dietlein M, Schicha H. Should all patients with thyroid nodules ≥ 1 cm undergo fine-needle aspiration biopsy? Nuklearmedizin 2018; 48:79-83. [DOI: 10.3413/nukmed-0313] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2009] [Indexed: 11/20/2022]
Abstract
SummaryThe prevalence of thyroid nodules . 1 cm is high in a previously iodine-deficient area. Under the hypothesis, that all patients with such nodules undergo fine-needle aspiration biopsy (FNAB) and that sensitivity and specificity of cytology are calculated with 85%, the positive predictive value of pathologic cytologic finding will reach 1.5% only according to Bayes-theorem. This is clinically unacceptable, as resection will be the consequence in all cases with suspect cytology. Even implementation of a second, independent test (e. g. moleculargenetic testing of thyreocytes, sensitivity to detect mutation 50%, specificity 95%) and application of sequential Bayestheorem the positive predictive value of combined pathologic findings will increase to 13% only. Nevertheless, 58% out of all thyroid cancer remain undetected by such a sequential algorithm.As a consequence, pre-selection of thyroid nodules for FNAB is required to increase the pretest-probability to at least 5.10%. A combination of sonographic criteria and scintigraphy, even in patients with normal TSHlevels, is suited to selected thyroid nodules for FNAB.
Collapse
|
235
|
Hörrmann F, Trendler G, Schmidt M, Häfner H, Maier W, Wagner M, Gaebel W, Wölwer W, Klosterkötter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S, Möller HJ, Bottlender R, Maurer K. Früherkennung des Psychoserisikos mit dem Early Recognition Inventory (ERIraos). ACTA ACUST UNITED AC 2018. [DOI: 10.1055/s-0038-1626434] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
ZusammenfassungDie Frühintervention bei schizophrenen Psychosen kann entweder im initialen Prodrom oder in der beginnenden ersten Episode stattfinden. Dies setzt eine zuverlässige Früherkennung von Risikopersonen voraus. Wir berichten über den Aufbau des zweistufigen Früherkennungsinventars ERIraos, bestehend aus einer Checkliste als Screeninginstrument und einer umfassenden Symptomliste und weiteren modularen Komponenten. Es werden erste Ergebnisse zur Reliabilität der Checkliste und zu ihrer Übereinstimmungsvalidität mit den interventionsrelevanten Einschlusskriterien berichtet.
Collapse
|
236
|
Abstract
SummaryAim: Targeted radiotherapies using iodine-131 meta-iodobenzylguanidin have long been in use for treatment of stage IV neuroblastoma but reliable dosimetric data are scarce. Method: This work presents an approach to determine the whole body exposure and tumour doses delivered during therapy. Dosimetric data are reported and discussed for six treatments carried out according to the trial protocol NB2004 as it is in use in our study in the last two years. Results: Whole body exposures are found to be in the range of 1.75 to 2.5 Gy whereas tumour doses vary between 15 and 55 Gy. Conclusion: The course of action prescribed by the trial protocol allows whole body exposure as well as tumour doses to be determined routinely.
Collapse
|
237
|
Wieler H, Schmidt M, Schwab R, Goretzki PE, Schicha H, Dietlein M. Routine measurement of serum calcitonin in patients with nodular thyroid disorders? Nuklearmedizin 2018. [DOI: 10.1055/s-0037-1621034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryIn spite of the fact that the German Society of Endocrinology has recommended calcitonin as screening-parameter the majority of physicians in Germany do not routinely use calcitonin in patients with thyroid nodules to exclude medullary thyroid cancer (MTC). The future revision of the recommendation should describe reference values for each commercially available assay, separately for men and women (basal and after pentagastrin-stimulation), and should define sonomorphological inclusion criteria. The epidemiological database of the prevalence of MTC is controversial and the specificity of basal elevated calcitonin levels is limited up to the 5-fold of the upper reference level. If renal insufficiency, bacterial infection, and an alcohol- or druginduced stimulation of calcitonin is excluded, hypercalcitoninaemia should be confirmed by a second measurement (if necessary using another assay). Stimulation of calcitonin by use of pentagastrin is mandatory prior to the decision on thyroidectomy. A stimulated calcitonin level <100 pg/ ml justifies “wait and see”. If stimulated calcitonin levels range between 100 and 200 pg/ml or higher, the differentiation between C-cell hyperplasia and MTC remains uncertain, especially in men. The implementation of calcitonin- screening requires the definition of sonographic inclusion criteria and validation of each assay. Additional prerequisites are excellent logistic (short period between blood sampling and start of the laboratory test), knowledge of differential diagnoses, knowledge of the consumption of drugs and alcohol, availability of pentagastrin-testing and of moleculargenetic testing with full information to the patients and sufficient time before the decision on surgery is made. All this and the choice of a skilled surgeon, experienced in thyroidectomy and lymphadenectomy with a low rate of local complications are the rationale to recommend calcitonin-screening primarily in centers for thyroid disorders.
Collapse
|
238
|
Schmalenbach M, Jungehülsing M, Theissen P, Dietlein M, Schröder U, Eschner W, Stennert E, Schicha H, Schmidt M. 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625597] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Aim: Assessment of the clinical value of 18F-FDG-PET for detection of recurrent head and neck cancer, local lymph node involvement and distant metastases comparing a qualitative visual with a semiquantitative analysis (SUV values). Patients, methods: Retrospective evaluation of 73 18F-FDG PET studies in 55 patients by use of a four-step qualitative visual grading system and calculation of standard uptake values in pathological lesions. Calculation of SUV values in normal regions for generating a map of physiological 18F-FDG distribution. Correlation to histopathological findings and clinical follow-up. Results: 1. Qualitative visual analysis of 18F-FDG PET studies: a) local recurrence sensitivity 79%, specificity 97%, positive predictive value 95%, negative predictive value 85%, and diagnostic accuracy 89%; b) local metastatic lymph nodes 100%, 95%, 85%, 100%, 96%; c) distant metastases 100%, 98%, 86%, 100%, 98%, respectively. 2. Semiquantitative analysis had only little incremental, non-significant value in comparison to qualitative visual analysis for the detection of a local recurrence in two patients: a) local recurrence: sensitivity 83%, specificity 100%, positive predictive value 100%, negative predictive value 88%, and diagnostic accuracy 93%; b) local metastatic lymph nodes or c) distant metastases did not change in comparison to qualitative visual analysis. Conclusion: 18F-FDG PET is an effective tool for re-staging of patients with suspected recurrence after therapy for head and neck cancer.
Collapse
|
239
|
Jockenhövel F, Theissen P, Dietlein M, Krone W, Schicha H, Schmidt M. Assessment of endocrine disorders of the hypothalamicpituitary axis by nuclear medicine techniques. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625645] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe following article reviews nuclear medicine techniques which can be used for assessment of endocrine disorders of the hypothalamic-pituitary axis. For planar and SPECT imaging somatostatin-receptor- and dopamine- D2-receptor-scintigraphy are the most widely distributed techniques. These nuclear medicine techniques may be indicated in selected cases to answer differential diagnostic problems. They can be helpful to search for presence and localization of receptor positive tissue. Furthermore they can detect metastasis in the rare cases of a pituitary carcinoma. Scintigraphy with Gallium-67 is suitable for further diagnostic evaluation in suspected hypophysitis. Other SPECT radiopharmaca do not have relevant clinical significance. F-18-FDG as PET radiopharmacon is not ideal because obvious pituitary adenomas could not be visualized. Other PET radiopharmaca including C-11-methionine, C-11-tyrosine, F-18-fluoroethylspiperone, C-11-methylspiperone, and C-11-raclopride are available in specialized centers only. Overall indications for nuclear medicine in studies for the assessment of endocrine disorders of the hypothalamic-pituitary-axis are rare. Original studies often report only about a small number of patients. According to the authors’ opinion the relevance of nuclear medicine in studies of clinically important endocrinologic fields, e. g. localization of small ACTH-producing pituitary adenomas, tumor localization in ectopic ACTH syndrome, localization of recurrent pituitary tissue, assessment of small incidentalomas, can not be definitely given yet.
Collapse
|
240
|
Abstract
SummaryThe need for therapy for nodular goiter results from the growth of thyroid nodules over decades and from the possibility of tracheal compression and worsening of respiratory function. Given the high prevalence of non-toxic goiter, the epidemiologically low incidence of clinically apparent thyroid cancer justifies non-surgical strategies. Randomised studies have shown that levothyroxine offers limited therapeutic effects and is inferior to radioiodine therapy regarding goiter shrinkage. When indication for a definitive therapy is given, the choice between resection and radioiodine therapy should consider volume of goiter, severity of clinical symptoms, thyroid uptake, patient’s age, co-morbidity, previous resection of goiter, patient’s profession and patient’s wish. Even in large goiters between 100 and 300 ml radioiodine therapy showed consistent results with goiter size reduction from 35-40% one year and 40-60% two years after radioiodine therapy. Thyroid hormones to prevent recurrence of goiter are not necessary. Recurrent goiters were seldom observed after radioiodine therapy and resulted from initially very large goiters or uptake in dominante nodules or from low 131I activities. Recombinant human TSH (rhTSH) offers the opportunity to enhance the effect of radioiodine therapy. Observational studies have shown that rhTSH increases low 131I uptake in case of high alimentary iodine-supply by the factor 4, causes a more homogenous 131I distribution within the goiter and improves goiter reduction. A phase I study for dose finding is running in the USA. Conclusion: Radioiodine therapy for shrinkage of large non-toxic goiter should not be restricted to elderly patients, or to patients with co-morbidity or high operative risk, but is an attractive alternative to surgery in patients with special professions (singer, teacher, speaker) or with the wish for a non-invasive treatment modality.
Collapse
|
241
|
Moka D, Schmidt M, Theissen P, Schicha H, Dietlein M. Prevention, screening and therapy of thyroid diseases and their cost-effectiveness. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625188] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary:Cost-effectiveness analyses focused on benign thyroid diseases are under-represented in the literature. The calculation of costs per additionally gained life year is difficult: The benefit of prevention is shifted into the distant future. The influence of an untreated subclinical thyroid disease on life expectancy can only be demonstrated by a long-term follow-up and by epidemiological databases. Iodine supplementation and programs for the prevention of tobacco smoking (primary prevention) are very cost-effective. Smoking increases the risk both of multinodular goiter and of Graves’ disease. Screening programs (secondary prevention) are discussed for the laboratory parameters thyrotropin (TSH), calcium and calcitonin. TSH testing seems to be very cost-effective for epidemiological considerations in a certain lifespan (newborn, pregnancy, postpartal, older persons, hospitalisation due to acute diseases) and in persons with previously elevated TPO-antibodies or TSH-values >2 mU/l, but dedicated cost-effectiveness analyses are lacking. On the other hand, the cost-effectiveness of a routine TSH testing beyond the age of 35 years has been shown by a high-quality decision analysis. Therapeutic strategies (tertiary prevention) aim at the avoidance of complications (atrial fibrillation, myocardial infarction, death for cardiac reasons) and of iatrogenic complications. Examples of a tertiary prevention are: firstly the definitive therapy of Graves’ disease in patients who have an increased risk of relapse after antithyroid drugs (ATD), secondly the radioiodine therapy for subclinical hyperthyroidism and the radioiodine therapy of large goiters in older patients or in patients suffering from a relevant comorbidity. Cost-effectiveness analyses for different therapeutic strategies of Graves’ disease were published using a lifelong time-horizon. The ablative radioiodine dose-regime is cost-effective as a first line therapy if the risk of relapse after ATD exceeds 60%.
Collapse
|
242
|
Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H, Schmidt M. Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625111] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryAim: 131I-meta-iodobenzylguanidine (131I-MIBG) therapy has been used in neuroblastoma treatment for many years but its value in high intensive first line treatment protocols is not exactly known. Patients, methods: Stage 4 neuroblastoma patients >1 year with 123I-MIBG positive residual disease (primary tumour and/or metastasis) after complete induction chemotherapy according to the German neuroblastoma trial NB97 were retrospectively analyzed. Results: One-hundred-eleven patients had 123I-MIBG positive residual disease after complete induction chemotherapy. Forty patients received 131I-MIBG therapy using a median activity of 0.44 GBq/kg body weight. By univariate analysis, patients who underwent 131I-MIBG therapy had a better 3-year event free survival (3-y-EFS 46±8%) and 3-year overall survival (3-y-OS 58±9%) than 71 patients without 131I-MIBG therapy (3-y-EFS 19±5%, p=0.003; 3-y-OS 43±6%, p=0.037). However, subgroup analysis of 66 patients who underwent high dose chemotherapy with autologous stem cell transplantation (ASCT) during treatment found a very similar outcome with 131I-MIBG therapy (3-y-EFS 49±9%, 3-y-OS 59±10%) and without 131I-MIBG therapy (3-y-EFS 33±9%, p=0.171; 3-y-OS 59±9%, p=0.285) due to the dominating effect of ASCT. By multivariate analysis, 131I-MIBG therapy had no impact on EFS (p=0.494) and OS (p=0.891). Only ASCT, external beam radiation therapy and MYCN amplification were important for EFS and OS. Conclusions: An independent advantage of I-131-MIBG therapy could not be proven in this retrospective analysis. The ongoing German Neuroblastoma Trial NB2004 will address the influence of 131I-MIBG therapy with emphasis on tumour dosimetry.
Collapse
|
243
|
Abstract
Ambipolar organic semiconductors are of high interest for organic field-effect transistors. For n-type conduction, low LUMO energies are required. Dibenzo[a,e]pentalenes (DBPs) are promising compounds; however, few derivatives exist with energetically low-lying LUMO levels. Here, we present DBP derivatives with LUMO energies down to -3.73 eV and small bandgaps down to 1.63 eV determined through cyclic voltammetry, UV/vis absorption spectroscopy, and TDDFT calculations. Single-crystal X-ray diffraction analysis revealed a 1D π-stacking mode. The addition of arylalkynyl substituents at the five-membered rings in a facile and versatile synthetic route allowed for tuning of the band gaps and LUMO energies. The synthetic route can easily be modified to access a variety of DBP derivatives. The LUMO energies of the DBP derivatives presented herein make them attractive for an application in n-type or ambipolar field-effect transistors.
Collapse
Affiliation(s)
- David C Grenz
- Institute for Organic Chemistry and ‡Institute for Inorganic and Analytical Chemistry, University of Freiburg , Albertstraße 21, 79104 Freiburg, Germany
| | - Maximilian Schmidt
- Institute for Organic Chemistry and ‡Institute for Inorganic and Analytical Chemistry, University of Freiburg , Albertstraße 21, 79104 Freiburg, Germany
| | - Daniel Kratzert
- Institute for Organic Chemistry and ‡Institute for Inorganic and Analytical Chemistry, University of Freiburg , Albertstraße 21, 79104 Freiburg, Germany
| | - Birgit Esser
- Institute for Organic Chemistry and ‡Institute for Inorganic and Analytical Chemistry, University of Freiburg , Albertstraße 21, 79104 Freiburg, Germany
| |
Collapse
|
244
|
Abstract
SummaryInteractions between brain, psyche and thyroid are known from historical descriptions of thyroidectomy (Kocher) and hyperthyroidism. However, their importance is often underscored in clinical routine. Thyroid hormone deficiency during pregnancy may result in irreversible mental retardation and requires levothyroxine substitution. TSH screening after delivery must identify newborns with congenital hypothyroidism: An early levothyroxine substitution and long term therapy control are required.Hypothyroidism and depression have many symptoms in common. Cognitive deficits and depressive states are often found in overt hypothyroidism, psychotic derangements are rare. Levothyroxine improves hypothyroid symptoms and mental performance, mood and motivation. Psychic symptoms of hyperthyroidism include agitation, irritability, mood disturbances, hyperactivity, anxiousness and even panic attacks. Manic and delusional states are rare. In geriatric patients hyperthyroidism may be oligosymptomatic. In psychiatric patients more frequent but unspecific disturbances of thyroid laboratory values being reversible without specific therapy have to be distinguished from rather rare but causative organic thyroid diseases with therapeutic consequences. Some psychiatric drugs influence thyroid laboratory results. Hypothyroidism in depressive patients is a negative prognostic parameter and requires therapy. Psychiatric symptoms associated with hypothyroidism are usually reversible under levothyroxine within 4–8 weeks. The standard for hypothyroidism is mono-levothyroxine therapy.
Collapse
|
245
|
Abstract
SummarySeveral population-based studies have shown a significant association between TSH-level and BMI (body mass index). About 30% of the rest energy expenditure are regulated by thyroid hormones, which generated the hypothesis that thyroid hormone substitution with TSH-titration into the lower reference levels may prevent body weight gain. The opposite effect of thyroid hormones is appetite stimulation, which may be responsible for body weight gain in case of substitutive medication.The association between TSH and BMI has become a complex topic in the light of the endocrine activity of adipocytes. Adipocytes are not a silent fat mass, but increase the hormone level of leptin, which influences neurones in the hypothalamus, the thyreotropic axis and TSH secretion. BMI is positively correlated with serum leptin. Elevated leptin levels, endogenous in individuals with high BMI or exogenous after leptin injection for treatment of hypothalamic amenorrhoea, shift TSH in the upper reference level. Borderline elevated TSH levels are reversible in case of body weight reduction in obese persons. It remains unclear whether high TSH levels or high leptin level are responsible for obesity or represent secondary phenomenon.
Recommendation for daily practice: Borderline elevated TSH-levels in obese patients will decrease in case of body weight reduction without hormone medication. After definitive treatment of hyperthyroidism patient's history for use of carbohydrates (increased during hyperthyroidism) should be noticed and substitution with thyroid hormones aims at TSH in the lower reference level. As body weight gain is observed in all TSH groups, a special concept for prevention and therapy of obesity (diet, daily exercise, behaviour training) should be initiated early and additionally to medication.
Collapse
|
246
|
Abstract
SummaryThe German translation of the EANM guideline for MIBG scintigraphy in children (Olivier P et al. EJNM MI 2003; 30: B45–B50; Hahn K. Der Nuklearmediziner 2002; 25: 101–105) was reviewed and actualized according to current publications, legal requirements and conditions in Germany. For the first time this guideline was generated in consensus with the neuroblastoma study group of the Association of Paediatric Haematologie and Oncology (GPOH) with the result of an interdisciplinary recommendation. Further main alterations are related to the recommended 123I activities with respect to the new EANM Paediatric Dosage Card and the explicit recommendation of SPECT.
Collapse
|
247
|
Abstract
SummaryAim: This study was performed to analyse the impact of the choice of antithyroid drugs (ATD) on the outcome of ablative radioiodine therapy (RIT) in patients with Graves' disease. Patients, material, methods: A total of 571 consecutive patients were observed for 12 months after RIT between July 2001 and June 2004. Inclusion criteria were the confirmed diagnosis of Graves' disease, compensation of hyperthyroidism and withdrawal of ATD two days before preliminary radioiodine-testing and RIT. The intended dose of 250 Gy was calculated from the results of the radioiodine test and the therapeutically achieved dose was measured by serial uptake measurements. The end-point measure was thyroid function 12 months after RIT; success was defined as elimination of hyperthyroidism. The pretreatment ATD was retrospectively correlated with the results achieved. Results: Relief from hyperthyroidism was achieved in 96 % of patients. 472 patients were treated with carbimazole or methimazole (CMI) and 61 with propylthiouracil (PTU). 38 patients had no thyrostatic drugs (ND) prior to RIT. The success rate was equal in all groups (CMI 451/472; PTU 61/61; ND 37/38; p=0.22). Conclusion: Thyrostatic treatment with PTU achieves excellent results in ablative RIT, using an accurate dosimetric approach with an achieved post-therapeutic dose of more than 200 Gy.
Collapse
|
248
|
Thoma N, Dietlein M, Moka D, Eschner W, Faust M, Schröder W, von Hülst-Schlabrendorff M, Ehses W, Schicha H, Schmidt M. 99mTc-MIBI SPECT in primary hyperparathyroidism. Nuklearmedizin 2018. [DOI: 10.3413/nukmed-0057] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
SummaryAim of the study was to analyse the influence of a concomitant vitamin D deficiency on the results of 99mTc-MIBI studies in patients (pts) with primary hyperparathyroidism (pHPT). Patients, methods: Between January 1998 and May 2004, 71 pts with pHPT had undergone operation after a 99mTc-MIBI study of whom 54 pts (76%) had normal values of 25-OH-vitamin D3 and 17 pts (24%) had vitamin D deficiency. Results of a dual-phase 99mTc-MIBI protocol with SPECT were compared with histopathology. Results: In 54 pts with normal vitamin D values late SPECT images identified more lesions (n = 51, sensitivity 91%) than early planar (n = 45, sensitivity 82%) or late planar images (n = 50, sensitivity 88%). In 17 pts with vitamin D deficiency late SPECT images identified more lesions (n = 13, sensitivity 72%) than early planar (n = 10, sensitivity 56%) or late planar images (n = 10, sensitivity 56%) too. In pts with vitamin D deficiency the sensitivity of a 99mTc-MIBI SPECT study was lower than in those with normal vitamin D status (72% vs. 91%) and dependent on the value for PTH. However, the results did not reach statistical significance: early planar: p = 0.1625; late planar: p = 0.0039; 99mTc-MIBI SPECT: p = 0.1180. Conclusion: The likelihood of a pathological 99mTc-MIBI study being obtained in pts with pHPT is dependent on the parathyroid hormone level. However, a negative influence of a low vitamin D level on the scintigraphic detection rate of a parathyroid adenoma could not be proven which may be due to the low number of pts with vitamin D deficiency.
Collapse
|
249
|
Campbell BCV, van Zwam WH, Goyal M, Menon BK, Dippel DWJ, Demchuk AM, Bracard S, White P, Dávalos A, Majoie CBLM, van der Lugt A, Ford GA, de la Ossa NP, Kelly M, Bourcier R, Donnan GA, Roos YBWEM, Bang OY, Nogueira RG, Devlin TG, van den Berg LA, Clarençon F, Burns P, Carpenter J, Berkhemer OA, Yavagal DR, Pereira VM, Ducrocq X, Dixit A, Quesada H, Epstein J, Davis SM, Jansen O, Rubiera M, Urra X, Micard E, Lingsma HF, Naggara O, Brown S, Guillemin F, Muir KW, van Oostenbrugge RJ, Saver JL, Jovin TG, Hill MD, Mitchell PJ, Berkhemer OA, Fransen PSS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJH, van Walderveen MAA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama à Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle J, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach Z, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Wakhloo A, Moonis M, Henninger N, Goddeau R, Massari F, Minaeian A, Lozano JD, Ramzan M, Stout C, Patel A, Majoie CB, Tunguturi A, Onteddu S, Carandang R, Howk M, Ribó M, Sanjuan E, Rubiera M, Pagola J, Flores A, Muchada M, Dippel DW, Meler P, Huerga E, Gelabert S, Coscojuela P, Tomasello A, Rodriguez D, Santamarina E, Maisterra O, Boned S, Seró L, Brown MM, Rovira A, Molina CA, Millán M, Muñoz L, Pérez de la Ossa N, Gomis M, Dorado L, López-Cancio E, Palomeras E, Munuera J, Liebig T, García Bermejo P, Remollo S, Castaño C, García-Sort R, Cuadras P, Puyalto P, Hernández-Pérez M, Jiménez M, Martínez-Piñeiro A, Lucente G, Stijnen T, Dávalos A, Chamorro A, Urra X, Obach V, Cervera A, Amaro S, Llull L, Codas J, Balasa M, Navarro J, Andersson T, Ariño H, Aceituno A, Rudilosso S, Renu A, Macho JM, San Roman L, Blasco J, López A, Macías N, Cardona P, Mattle H, Quesada H, Rubio F, Cano L, Lara B, de Miquel MA, Aja L, Serena J, Cobo E, Albers GW, Lees KR, Wahlgren N, Arenillas J, Roberts R, Minhas P, Al-Ajlan F, Salluzzi M, Zimmel L, Patel S, Eesa M, Martí-Fàbregas J, Jankowitz B, van der Heijden E, Serena J, Salvat-Plana M, López-Cancio E, Bracard S, Ducrocq X, Anxionnat R, Baillot PA, Barbier C, Derelle AL, Lacour JC, Ghannouti N, Richard S, Samson Y, Sourour N, Baronnet-Chauvet F, Clarencon F, Crozier S, Deltour S, Di Maria F, Le Bouc R, Leger A, Fleitour N, Mutlu G, Rosso C, Szatmary Z, Yger M, Zavanone C, Bakchine S, Pierot L, Caucheteux N, Estrade L, Kadziolka K, Hooijenga I, Leautaud A, Renkes C, Serre I, Desal H, Guillon B, Boutoleau-Bretonniere C, Daumas-Duport B, De Gaalon S, Derkinderen P, Evain S, Puppels C, Herisson F, Laplaud DA, Lebouvier T, Lintia-Gaultier A, Pouclet-Courtemanche H, Rouaud T, Rouaud Jaffrenou V, Schunck A, Sevin-Allouet M, Toulgoat F, Pellikaan W, Wiertlewski S, Gauvrit JY, Ronziere T, Cahagne V, Ferre JC, Pinel JF, Raoult H, Mas JL, Meder JF, Al Najjar-Carpentier AA, Geerling A, Birchenall J, Bodiguel E, Calvet D, Domigo V, Godon-Hardy S, Guiraud V, Lamy C, Majhadi L, Morin L, Naggara O, Lindl-Velema A, Trystram D, Turc G, Berge J, Sibon I, Menegon P, Barreau X, Rouanet F, Debruxelles S, Kazadi A, Renou P, van Vemde G, Fleury O, Pasco-Papon A, Dubas F, Caroff J, Godard Ducceschi S, Hamon MA, Lecluse A, Marc G, Giroud M, Ricolfi F, de Ridder A, Bejot Y, Chavent A, Gentil A, Kazemi A, Osseby GV, Voguet C, Mahagne MH, Sedat J, Chau Y, Suissa L, Greebe P, Lachaud S, Houdart E, Stapf C, Buffon Porcher F, Chabriat H, Guedin P, Herve D, Jouvent E, Mawet J, Saint-Maurice JP, de Bont-Stikkelbroeck J, Schneble HM, Turjman F, Nighoghossian N, Berhoune NN, Bouhour F, Cho TH, Derex L, Felix S, Gervais-Bernard H, Gory B, de Meris J, Manera L, Mechtouff L, Ritzenthaler T, Riva R, Salaris Silvio F, Tilikete C, Blanc R, Obadia M, Bartolini MB, Gueguen A, Janssen K, Piotin M, Pistocchi S, Redjem H, Drouineau J, Neau JP, Godeneche G, Lamy M, Marsac E, Velasco S, Clavelou P, Struijk W, Chabert E, Bourgois N, Cornut-Chauvinc C, Ferrier A, Gabrillargues J, Jean B, Marques AR, Vitello N, Detante O, Barbieux M, Licher S, Boubagra K, Favre Wiki I, Garambois K, Tahon F, Ashok V, Voguet C, Coskun O, Guedin P, Rodesch G, Lapergue B, Boodt N, Bourdain F, Evrard S, Graveleau P, Decroix JP, Wang A, Sellal F, Ahle G, Carelli G, Dugay MH, Gaultier C, Ros A, Lebedinsky AP, Lita L, Musacchio RM, Renglewicz-Destuynder C, Tournade A, Vuillemet F, Montoro FM, Mounayer C, Faugeras F, Gimenez L, Venema E, Labach C, Lautrette G, Denier C, Saliou G, Chassin O, Dussaule C, Melki E, Ozanne A, Puccinelli F, Sachet M, Slokkers I, Sarov M, Bonneville JF, Moulin T, Biondi A, De Bustos Medeiros E, Vuillier F, Courtheoux P, Viader F, Apoil-Brissard M, Bataille M, Ganpat RJ, Bonnet AL, Cogez J, Kazemi A, Touze E, Leclerc X, Leys D, Aggour M, Aguettaz P, Bodenant M, Cordonnier C, Mulder M, Deplanque D, Girot M, Henon H, Kalsoum E, Lucas C, Pruvo JP, Zuniga P, Bonafé A, Arquizan C, Costalat V, Saiedie N, Machi P, Mourand I, Riquelme C, Bounolleau P, Arteaga C, Faivre A, Bintner M, Tournebize P, Charlin C, Darcel F, Heshmatollah A, Gauthier-Lasalarie P, Jeremenko M, Mouton S, Zerlauth JB, Lamy C, Hervé D, Hassan H, Gaston A, Barral FG, Garnier P, Schipperen S, Beaujeux R, Wolff V, Herbreteau D, Debiais S, Murray A, Ford G, Muir KW, White P, Brown MM, Clifton A, Vinken S, Freeman J, Ford I, Markus H, Wardlaw J, Lees KR, Molyneux A, Robinson T, Lewis S, Norrie J, Robertson F, van Boxtel T, Perry R, Dixit A, Cloud G, Clifton A, Madigan J, Roffe C, Nayak S, Lobotesis K, Smith C, Herwadkar A, Koets J, Kandasamy N, Goddard T, Bamford J, Subramanian G, Lenthall R, Littleton E, Lamin S, Storey K, Ghatala R, Banaras A, Boers M, Aeron-Thomas J, Hazel B, Maguire H, Veraque E, Harrison L, Keshvara R, Cunningham J, Santos E, Borst J, Jansen I, Kappelhof M, Lucas M, Geuskens R, Barros RS, Dobbe R, Csizmadia M, Hill MD, Goyal M, Demchuk AM, Menon BK, Eesa M, Ryckborst KJ, Wright MR, Kamal NR, Andersen L, Randhawa PA, Stewart T, Patil S, Minhas P, Almekhlafi M, Mishra S, Clement F, Sajobi T, Shuaib A, Montanera WJ, Roy D, Silver FL, Jovin TG, Frei DF, Sapkota B, Rempel JL, Thornton J, Williams D, Tampieri D, Poppe AY, Dowlatshahi D, Wong JH, Mitha AP, Subramaniam S, Hull G, Lowerison MW, Sajobi T, Salluzzi M, Wright MR, Maxwell M, Lacusta S, Drupals E, Armitage K, Barber PA, Smith EE, Morrish WF, Coutts SB, Derdeyn C, Demaerschalk B, Yavagal D, Martin R, Brant R, Yu Y, Willinsky RA, Montanera WJ, Weill A, Kenney C, Aram H, Stewart T, Stys PK, Watson TW, Klein G, Pearson D, Couillard P, Trivedi A, Singh D, Klourfeld E, Imoukhuede O, Nikneshan D, Blayney S, Reddy R, Choi P, Horton M, Musuka T, Dubuc V, Field TS, Desai J, Adatia S, Alseraya A, Nambiar V, van Dijk R, Wong JH, Mitha AP, Morrish WF, Eesa M, Newcommon NJ, Shuaib A, Schwindt B, Butcher KS, Jeerakathil T, Buck B, Khan K, Naik SS, Emery DJ, Owen RJ, Kotylak TB, Ashforth RA, Yeo TA, McNally D, Siddiqui M, Saqqur M, Hussain D, Kalashyan H, Manosalva A, Kate M, Gioia L, Hasan S, Mohammad A, Muratoglu M, Williams D, Thornton J, Cullen A, Brennan P, O'Hare A, Looby S, Hyland D, Duff S, McCusker M, Hallinan B, Lee S, McCormack J, Moore A, O'Connor M, Donegan C, Brewer L, Martin A, Murphy S, O'Rourke K, Smyth S, Kelly P, Lynch T, Daly T, O'Brien P, O'Driscoll A, Martin M, Daly T, Collins R, Coughlan T, McCabe D, Murphy S, O'Neill D, Mulroy M, Lynch O, Walsh T, O'Donnell M, Galvin T, Harbison J, McElwaine P, Mulpeter K, McLoughlin C, Reardon M, Harkin E, Dolan E, Watts M, Cunningham N, Fallon C, Gallagher S, Cotter P, Crowe M, Doyle R, Noone I, Lapierre M, Coté VA, Lanthier S, Odier C, Durocher A, Raymond J, Weill A, Daneault N, Deschaintre Y, Jankowitz B, Baxendell L, Massaro L, Jackson-Graves C, Decesare S, Porter P, Armbruster K, Adams A, Billigan J, Oakley J, Ducruet A, Jadhav A, Giurgiutiu DV, Aghaebrahim A, Reddy V, Hammer M, Starr M, Totoraitis V, Wechsler L, Streib S, Rangaraju S, Campbell D, Rocha M, Gulati D, Silver FL, Krings T, Kalman L, Cayley A, Williams J, Stewart T, Wiegner R, Casaubon LK, Jaigobin C, del Campo JM, Elamin E, Schaafsma JD, Willinsky RA, Agid R, Farb R, ter Brugge K, Sapkoda BL, Baxter BW, Barton K, Knox A, Porter A, Sirelkhatim A, Devlin T, Dellinger C, Pitiyanuvath N, Patterson J, Nichols J, Quarfordt S, Calvert J, Hawk H, Fanale C, Frei DF, Bitner A, Novak A, Huddle D, Bellon R, Loy D, Wagner J, Chang I, Lampe E, Spencer B, Pratt R, Bartt R, Shine S, Dooley G, Nguyen T, Whaley M, McCarthy K, Teitelbaum J, Tampieri D, Poon W, Campbell N, Cortes M, Dowlatshahi D, Lum C, Shamloul R, Robert S, Stotts G, Shamy M, Steffenhagen N, Blacquiere D, Hogan M, AlHazzaa M, Basir G, Lesiuk H, Iancu D, Santos M, Choe H, Weisman DC, Jonczak K, Blue-Schaller A, Shah Q, MacKenzie L, Klein B, Kulandaivel K, Kozak O, Gzesh DJ, Harris LJ, Khoury JS, Mandzia J, Pelz D, Crann S, Fleming L, Hesser K, Beauchamp B, Amato-Marzialli B, Boulton M, Lopez- Ojeda P, Sharma M, Lownie S, Chan R, Swartz R, Howard P, Golob D, Gladstone D, Boyle K, Boulos M, Hopyan J, Yang V, Da Costa L, Holmstedt CA, Turk AS, Navarro R, Jauch E, Ozark S, Turner R, Phillips S, Shankar J, Jarrett J, Gubitz G, Maloney W, Vandorpe R, Schmidt M, Heidenreich J, Hunter G, Kelly M, Whelan R, Peeling L, Burns PA, Hunter A, Wiggam I, Kerr E, Watt M, Fulton A, Gordon P, Rennie I, Flynn P, Smyth G, O'Leary S, Gentile N, Linares G, McNelis P, Erkmen K, Katz P, Azizi A, Weaver M, Jungreis C, Faro S, Shah P, Reimer H, Kalugdan V, Saposnik G, Bharatha A, Li Y, Kostyrko P, Santos M, Marotta T, Montanera W, Sarma D, Selchen D, Spears J, Heo JH, Jeong K, Kim DJ, Kim BM, Kim YD, Song D, Lee KJ, Yoo J, Bang OY, Rho S, Lee J, Jeon P, Kim KH, Cha J, Kim SJ, Ryoo S, Lee MJ, Sohn SI, Kim CH, Ryu HG, Hong JH, Chang HW, Lee CY, Rha J, Davis SM, Donnan GA, Campbell BCV, Mitchell PJ, Churilov L, Yan B, Dowling R, Yassi N, Oxley TJ, Wu TY, Silver G, McDonald A, McCoy R, Kleinig TJ, Scroop R, Dewey HM, Simpson M, Brooks M, Coulton B, Krause M, Harrington TJ, Steinfort B, Faulder K, Priglinger M, Day S, Phan T, Chong W, Holt M, Chandra RV, Ma H, Young D, Wong K, Wijeratne T, Tu H, Mackay E, Celestino S, Bladin CF, Loh PS, Gilligan A, Ross Z, Coote S, Frost T, Parsons MW, Miteff F, Levi CR, Ang T, Spratt N, Kaauwai L, Badve M, Rice H, de Villiers L, Barber PA, McGuinness B, Hope A, Moriarty M, Bennett P, Wong A, Coulthard A, Lee A, Jannes J, Field D, Sharma G, Salinas S, Cowley E, Snow B, Kolbe J, Stark R, King J, Macdonnell R, Attia J, D'Este C, Saver JL, Goyal M, Diener HC, Levy EI, Bonafé A, Mendes Pereira V, Jahan R, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, von Kummer R, Smith W, Turjman F, Hamilton S, Chiacchierini R, Amar A, Sanossian N, Loh Y, Devlin T, Baxter B, Hawk H, Sapkota B, Quarfordt S, Sirelkhatim A, Dellinger C, Barton K, Reddy VK, Ducruet A, Jadhav A, Horev A, Giurgiutiu DV, Totoraitis V, Hammer M, Jankowitz B, Wechsler L, Rocha M, Gulati D, Campbell D, Star M, Baxendell L, Oakley J, Siddiqui A, Hopkins LN, Snyder K, Sawyer R, Hall S, Costalat V, Riquelme C, Machi P, Omer E, Arquizan C, Mourand I, Charif M, Ayrignac X, Menjot de Champfleur N, Leboucq N, Gascou G, Moynier M, du Mesnil de Rochemont R, Singer O, Berkefeld J, Foerch C, Lorenz M, Pfeilschifer W, Hattingen E, Wagner M, You SJ, Lescher S, Braun H, Dehkharghani S, Belagaje SR, Anderson A, Lima A, Obideen M, Haussen D, Dharia R, Frankel M, Patel V, Owada K, Saad A, Amerson L, Horn C, Doppelheuer S, Schindler K, Lopes DK, Chen M, Moftakhar R, Anton C, Smreczak M, Carpenter JS, Boo S, Rai A, Roberts T, Tarabishy A, Gutmann L, Brooks C, Brick J, Domico J, Reimann G, Hinrichs K, Becker M, Heiss E, Selle C, Witteler A, Al-Boutros S, Danch MJ, Ranft A, Rohde S, Burg K, Weimar C, Zegarac V, Hartmann C, Schlamann M, Göricke S, Ringlestein A, Wanke I, Mönninghoff C, Dietzold M, Budzik R, Davis T, Eubank G, Hicks WJ, Pema P, Vora N, Mejilla J, Taylor M, Clark W, Rontal A, Fields J, Peterson B, Nesbit G, Lutsep H, Bozorgchami H, Priest R, Ologuntoye O, Barnwell S, Dogan A, Herrick K, Takahasi C, Beadell N, Brown B, Jamieson S, Hussain MS, Russman A, Hui F, Wisco D, Uchino K, Khawaja Z, Katzan I, Toth G, Cheng-Ching E, Bain M, Man S, Farrag A, George P, John S, Shankar L, Drofa A, Dahlgren R, Bauer A, Itreat A, Taqui A, Cerejo R, Richmond A, Ringleb P, Bendszus M, Möhlenbruch M, Reiff T, Amiri H, Purrucker J, Herweh C, Pham M, Menn O, Ludwig I, Acosta I, Villar C, Morgan W, Sombutmai C, Hellinger F, Allen E, Bellew M, Gandhi R, Bonwit E, Aly J, Ecker RD, Seder D, Morris J, Skaletsky M, Belden J, Baker C, Connolly LS, Papanagiotou P, Roth C, Kastrup A, Politi M, Brunner F, Alexandrou M, Merdivan H, Ramsey C, Given II C, Renfrow S, Deshmukh V, Sasadeusz K, Vincent F, Thiesing JT, Putnam J, Bhatt A, Kansara A, Caceves D, Lowenkopf T, Yanase L, Zurasky J, Dancer S, Freeman B, Scheibe-Mirek T, Robison J, Rontal A, Roll J, Clark D, Rodriguez M, Fitzsimmons BFM, Zaidat O, Lynch JR, Lazzaro M, Larson T, Padmore L, Das E, Farrow-Schmidt A, Hassan A, Tekle W, Cate C, Jansen O, Cnyrim C, Wodarg F, Wiese C, Binder A, Riedel C, Rohr A, Lang N, Laufs H, Krieter S, Remonda L, Diepers M, Añon J, Nedeltchev K, Kahles T, Biethahn S, Lindner M, Chang V, Gächter C, Esperon C, Guglielmetti M, Arenillas Lara JF, Martínez Galdámez M, Calleja Sanz AI, Cortijo Garcia E, Garcia Bermejo P, Perez S, Mulero Carrillo P, Crespo Vallejo E, Ruiz Piñero M, Lopez Mesonero L, Reyes Muñoz FJ, Brekenfeld C, Buhk JH, Krützelmann A, Thomalla G, Cheng B, Beck C, Hoppe J, Goebell E, Holst B, Grzyska U, Wortmann G, Starkman S, Duckwiler G, Jahan R, Rao N, Sheth S, Ng K, Noorian A, Szeder V, Nour M, McManus M, Huang J, Tarpley J, Tateshima S, Gonzalez N, Ali L, Liebeskind D, Hinman J, Calderon-Arnulphi M, Liang C, Guzy J, Koch S, DeSousa K, Gordon-Perue G, Haussen D, Elhammady M, Peterson E, Pandey V, Dharmadhikari S, Khandelwal P, Malik A, Pafford R, Gonzalez P, Ramdas K, Andersen G, Damgaard D, Von Weitzel-Mudersbach P, Simonsen C, Ruiz de Morales Ayudarte N, Poulsen M, Sørensen L, Karabegovich S, Hjørringgaard M, Hjort N, Harbo T, Sørensen K, Deshaies E, Padalino D, Swarnkar A, Latorre JG, Elnour E, El-Zammar Z, Villwock M, Farid H, Balgude A, Cross L, Hansen K, Holtmannspötter M, Kondziella D, Hoejgaard J, Taudorf S, Soendergaard H, Wagner A, Cronquist M, Stavngaard T, Cortsen M, Krarup LH, Hyldal T, Haring HP, Guggenberger S, Hamberger M, Trenkler J, Sonnberger M, Nussbaumer K, Dominger C, Bach E, Jagadeesan BD, Taylor R, Kim J, Shea K, Tummala R, Zacharatos H, Sandhu D, Ezzeddine M, Grande A, Hildebrandt D, Miller K, Scherber J, Hendrickson A, Jumaa M, Zaidi S, Hendrickson T, Snyder V, Killer-Oberpfalzer M, Mutzenbach J, Weymayr F, Broussalis E, Stadler K, Jedlitschka A, Malek A, Mueller-Kronast N, Beck P, Martin C, Summers D, Day J, Bettinger I, Holloway W, Olds K, Arkin S, Akhtar N, Boutwell C, Crandall S, Schwartzman M, Weinstein C, Brion B, Prothmann S, Kleine J, Kreiser K, Boeckh-Behrens T, Poppert H, Wunderlich S, Koch ML, Biberacher V, Huberle A, Gora-Stahlberg G, Knier B, Meindl T, Utpadel-Fischler D, Zech M, Kowarik M, Seifert C, Schwaiger B, Puri A, Hou S. Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data. Lancet Neurol 2018; 17:47-53. [DOI: 10.1016/s1474-4422(17)30407-6] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 10/05/2017] [Accepted: 10/11/2017] [Indexed: 10/18/2022]
|
250
|
Meixner M, Hellmich M, Dietlein M, Kobe C, Schicha H, Schmidt M. Disease-free survival in papillary and follicular thyroid carcinoma. Nuklearmedizin 2017; 52:71-80. [DOI: 10.3413/nukmed-0530-12-09] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Accepted: 01/21/2013] [Indexed: 12/16/2022]
Abstract
SummaryT stage was redefined for patients with differentiated thyroid carcinoma (DTC) between the 5th and 7th versions of the UICC tumour classification system. Patients, methods: 636 patients (486 women, 150 men; mean age 49.1 ± 15.6 years, mean follow-up 4.6 years) who had been treated with ablative radioiodine therapy after thyroidectomy for papillary (PTC) or follicular thyroid carcinomas (FTC) were retrospectively assessed on occurrence of locoregional recurrent disease, or cervical lymph node or distant metastases. Disease-free survival was calculated from initial T stage, classified according to both versions of the UICC staging system and compared with the prognostic value of primary tumour size. Kaplan-Meier method and two measures of explained variation, (1) R2 based on the (partial) likelihood ratio statistic of the Cox proportional hazards model and (2) a model-free variant of a distance measure proposed by Schemper had the aim to detect the most advantageous classification. Results: Of the 508 patients with PTC, 11 (2.2%) developed a local recurrence, 37 (7.3%) cervical lymph node and 23 (4.5%) distant metastases, 3 (2.3%), 8 (6.3%), and 18 (14.1%) were the numbers for the 128 FTC patients respectively. The two classification systems yielded an equal count of statistically significant differences regarding disease-free survival in patients with PTC while UICC 7th classification appeared slightly advantageous in patients with FTC. Regarding explained variation the UICC 7th classification tended to be superior to the UICC 5th classification, both in PTC and FTC, however statistical significance was not reached. Conclusion: The primary tumour size significantly added to the prognosis regarding local cervical and distant metastases.
Collapse
|